



Volume 23 No. 2 July 2016

p-ISSN 0853-442X

e-ISSN 2355-1402

# Indonesian Journal of Urology

## Jurnal Urologi Indonesia

**URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN AND CREATININE SERUM BPH PATIENTS WITH ACUTE URINE RETENTION TO DETECT KIDNEY FUNCTION DISORDERS**

**BODY MASS INDEX RELATIONS WITH THE DIFFICULTIES AND COMPLICATIONS OF PERCUTANEOUS NEPHROLITHOTOMY**

**CORRELATION BETWEEN BLOOD SERUM PSA LEVEL AND MMP-2 IN PROSTATE ADENOCARCINOMA**

**INITIAL EXPERIENCES WITH THREE RENAL ARTERIES OF KIDNEY ALLOGRAFT IN KIDNEY TRANSPLANTATION: A CASE SERIES**

**ETIOLOGY OF MALE INFERTILITY IN JAKARTA**

**DELAYED GRAFT FUNCTION FOLLOWING LAPAROSCOPIC LIVE DONOR NEPHRECTOMY: A MULTIVARIATE ANALYSIS**

**RELATION BETWEEN COMPLICATING FACTORS OF HYPOSPADIA AND COMPLICATIONS AFTER TIP: A RETROSPECTIVE STUDY**

**PERCUTANEOUS NEPHROSTOMY IN PATIENTS WITH OBSTRUCTIVE UROPATHY DUE TO MALIGNANCY: A SURVIVAL ANALYSIS**

**FACTORS ASSOCIATED WITH TUMOR RECURRENCE IN STAGE 1 BLADDER TRANSITIONAL CELL CARCINOMA IN SARDJITO HOSPITAL YOGYAKARTA**

**THE EFFICACY OF NASOGASTRIC TUBE IN A LARGE BLOOD CLOT EVACUATION DURING CYSTOSCOPY**

**MATURE RETROVESICAL TERATOMA IN AN ADULT MALE: A CASE REPORT AND LITERATURE REVIEW**

**SENSITIVITY AND SPECIFICITY OF URINALYSIS TO DIAGNOSE UTI IN PATIENTS WITH UROLITHIASIS AT SARDJITO GENERAL HOSPITAL**

**THE CORRELATIONS AMONG COMPONENTS OF METABOLIC SYNDROME, PSA, AND PROSTATE VOLUME IN BPH PATIENTS**

Indonesian Urological Association

JURI	Vol. 23	No. 2	Page 67 - 139	July 2016	p-ISSN 0853-442X e-ISSN 2355-1402
------	---------	-------	---------------	-----------	--------------------------------------

Accredited No. 81/DIKTI/Kep/2011

## Editorial Team

### EDITOR IN-CHIEF:

Dr. dr. Tarmono, SpU (K), (Department of Urology, Faculty of Medicine/Universitas Airlangga, Soetomo General Hospital, Surabaya)

### FOUNDER:

Prof. Dr. dr. Sunaryo Hardjowijoto, SpU(K), (Department of Urology, Faculty of Medicine/Universitas Airlangga, Soetomo General Hospital, Surabaya)

### SECTION EDITOR

dr. Fikri Rizaldi, SpU(K), (Department of Urology, Faculty of Medicine/Universitas Airlangga, Soetomo General Hospital, Surabaya)

### JOURNAL MANAGER

dr. M. Ayodhia Soebadi, SpU(K), (Department of Urology, Faculty of Medicine/Universitas Airlangga, Soetomo General Hospital, Surabaya)

### ETHICS EDITOR

Dr. dr. Besut Daryanto, SpU(K), (Division of Urology/Department of Surgery, Faculty of Medicine/Brawijaya University, Saiful Anwar General Hospital, Malang)

### ASSOCIATE EDITOR

#### BASIC SCIENCE RESEARCH

dr. Agus Rizal A.H. Hamid, PhD, SpU(K), (Department of Urology, Faculty of Medicine/Universitas Indonesia, Cipto Mangunkusumo General Hospital, Jakarta)

#### CLINICAL RESEARCH

Dr. dr. Wahjoe Djatisoesanto, SpU(K), (Department of Urology, Faculty of Medicine/Universitas Airlangga, Soetomo General Hospital, Surabaya)

#### TRANSLATIONAL RESEARCH

dr. Aaron Tigor Sihombing, SpU (K), (Department of Urology, Faculty of Medicine/Padjadjaran University, Hasan Sadikin General Hospital, Bandung)

### EDITORIAL BOARDS

Prof. Dr. dr. Akmal Taher, SpU(K), (Department of Urology, Faculty of Medicine/Universitas Indonesia, Cipto Mangunkusumo General Hospital, Jakarta)

Prof. Dr. dr. Soetojo, SpU (K), (Department of Urology, Faculty of Medicine/Universitas Airlangga, Soetomo General Hospital, Surabaya)

dr. I Wayan Yudiana, SpU, (Division of Urology/Department of Surgery, Faculty of Medicine/Udayana University, Sanglah General Hospital, Denpasar)

dr. Indrawarman, SpU, (Division of Urology/Department of Surgery, Faculty of Medicine/Gadjah Mada University, Sardjito General Hospital, Yogyakarta)

dr. Anugrah Dianfitriani, SpU, (KU Leuven-University of Leuven, Belgium)

### INTERNATIONAL EDITORIAL BOARDS

Prof. Seung-June Oh, MD, (Department of Urology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea)

Dr. Sanjay Balwant Kulkarni, MBBS, MS, FRCS (Glasgow), Dip. Urology (London), (Center for Reconstructive Urethral Surgery, 3 Rajpath Society, Paud Road, Pune, India)

Prof. Eric Chung, MBBS, FRCS (Urol), (Department of Urology, Princess Alexandra Hospital, University of Queensland, Australia)

Prof. Shigeo Horie, M.D, Ph.D, (Department of Urology, Jutendo Hospital, Tokyo, Japan)



DOI: <https://doi.org/10.32421/juri.v23i2>  
 Published: 2016-04-20

## ARTICLES

### URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN AND CREATININE SERUM BPH PATIENTS WITH ACUTE URINE RETENTION TO DETECT KIDNEY FUNCTION DISORDERS

Septina Rahayu, Sunaryo Hardjowijoto, Tarmono Djojodimedjo, Mohammad Ayodhia Soebadi

[PDF](#)

### BODY MASS INDEX RELATIONS WITH THE DIFFICULTIES AND COMPLICATIONS OF PERCUTANEOUS NEPHROLITHOTOMY

Fauriski Febrian Prapiska, Sunaryo Hardjowijoto, Doddy M Soebadi, Tarmono Djojodimedjo

[PDF](#)

### CORRELATION BETWEEN BLOOD SERUM PSA LEVEL AND MMP-2 IN PROSTATE ADENOCARCINOMA

Anny Setijo Rahaju, Aniek Meidi, Gondo Mastutik, Sjahjenny Mustokoweni, Arifa Mustika

[PDF](#)

### INITIAL EXPERIENCES WITH THREE RENAL ARTERIES OF KIDNEY ALLOGRAFT IN KIDNEY TRANSPLANTATION: A CASE SERIES

Tommie Prasetyo, Nur Rasyid, Arry Rodjani

[PDF](#)

### ETIOLOGY OF MALE INFERTILITY IN JAKARTA

Ari Basukarno, Ponco Birowo, Nur Rasyid

[PDF](#)

### DELAYED GRAFT FUNCTION FOLLOWING LAPAROSCOPIC LIVE DONOR NEPHRECTOMY: A MULTIVARIATE ANALYSIS

Pande Made Wisnu Tirtayasa, Gerhard Reinaldi Situmorang, Arry Rodjani, Nur Rasyid

[PDF](#)

### RELATION BETWEEN COMPLICATING FACTORS OF HYPOSPADIA AND COMPLICATIONS AFTER TIP: A RETROSPECTIVE STUDY

Johannes Aritonang, Arry Rodjani, Irfan Wahyudi

[PDF](#)

### PERCUTANEOUS NEPHROSTOMY IN PATIENTS WITH OBSTRUCTIVE UROPATHY DUE TO MALIGNANCY: A SURVIVAL ANALYSIS

Prahara Yuri, Sungsang Rochadi

[PDF](#)

### FACTORS ASSOCIATED WITH TUMOR RECURRENCE IN STAGE 1 BLADDER TRANSITIONAL CELL CARCINOMA IN SARDJITO HOSPITAL YOGYAKARTA

donny eka putra, Trisula Utomo

[PDF](#)

### THE EFFICACY OF NASOGASTRIC TUBE IN A LARGE BLOOD CLOT EVACUATION DURING CYSTOSCOPY

Caesar Khairul Wallad, Jumadi Santoso, Kuncoro Adi

[PDF](#)

### MATURE RETROVESICAL TERATOMA IN AN ADULT MALE: A CASE REPORT AND LITERATURE REVIEW

Vera Vera, Ferry Safriadi

[PDF](#)

### Sensitivity and Specificity of Urinalysis to Diagnose Urinary Tract Infection (UTI) in Patients with Urolithiasis at RSUP Dr. Sardjito Hospital

Awang Dyan Purnomo, Untung Tranggono

[PDF](#)

### THE CORRELATIONS AMONG COMPONENTS OF METABOLIC SYNDROME PSA AND PROSTATE VOLUME IN BPH PATIENTS

Yanuar Wicaksana Sumasta, Danarto Danarto

[PDF](#)



# CORRELATION BETWEEN BLOOD SERUM PSA LEVEL AND MMP-2 IN PROSTATE ADENOCARCINOMA

<sup>1</sup>Anny Setijo Rahaju, <sup>1</sup>Aniek Meidi, <sup>1</sup>Gondo Mastutik, <sup>1</sup>Sjahjenny Mustokoweni, <sup>2</sup>Arifa Mustika.

<sup>1</sup>Department of Anatomic Pathology, Faculty of Medicine/Universitas Airlangga, Soetomo General Hospital Surabaya.

<sup>2</sup>Department of Pharmacology, Faculty of Medicine/Universitas Airlangga, Soetomo General Hospital Surabaya.

## ABSTRACT

**Objective:** This study aims to prove the correlation between Prostate Specific Antigen (PSA) blood level and Matrix Metalloproteinase-2 (MMP-2) expression in patients with prostate adenocarcinoma. **Material & method:** Prostate cancer patients' data from January 2009 to May 2012 were collected at the Department of Pathology, Soetomo General Hospital Surabaya. Data collected included patient medical documents, PSA blood examination, and histopathological examination. Histopathology slides and paraffin blocks of needle biopsies, Transurethral Resection of Prostate (TURP) and radical prostatectomy of prostate cancer patients were re-read, then the samples that met the inclusion criteria were stained by immunohistochemistry using antibodies MMP-2. **Results:** Data collection was done to obtain data samples of prostate cancer patients in 2009 to 2012 comprising as many as 22 patients between the ages of 52-91 years. Prostate adenocarcinoma in age of 70-79 was found in 8 patients, with a mean age of 68 years. PSA values obtained from medical documents were between 8.6-594.41 ng/ml. Spearman's test performed in this study showed a positive correlation (one-tailed) (correlation coefficient ( $r$ ) 0.431,  $p < 0.05$ ) between blood PSA level and MMP-2 expression in patients with prostate adenocarcinoma. **Conclusion:** Blood PSA level correlates positively with MMP-2 expression in prostate adenocarcinoma.

**Keywords:** Prostate specific antigen, matrix metalloproteinase-2, prostate adenocarcinoma.

## ABSTRAK

**Tujuan:** Penelitian ini bertujuan untuk membuktikan hubungan antara kadar Prostate Specific Antigen (PSA) darah dengan Ekspresi Matrix Metalloproteinase-2 (MMP-2) pada penderita Adenokarsinoma Prostat. **Bahan & cara:** Data arsip penderita kanker Prostat dikumpulkan di Departemen/SMF/Instalasi Patologi Anatomi RSUD Dr. Soetomo Surabaya, mulai Januari 2009 sampai Mei 2012. Pengumpulan data meliputi dokumen medik penderita, data pemeriksaan PSA darah, dan data pemeriksaan Histopatologi. Slide Histopatologi dan blok parafin hasil biopsi jarum, Transurethral Resection of Prostate (TURP) dan Radikal Prostatectomy penderita kanker prostat dibaca ulang, kemudian sampel memenuhi kriteria inklusi dipulas secara imunohistokimia dengan menggunakan antibodi MMP-2. **Hasil:** Pengumpulan data yang dilakukan memperoleh data sampel penderita kanker prostat pada tahun 2009 sampai 2012 sebanyak 22 orang, yang terjadi antara usia 52-91 tahun. Adenokarsinoma prostat terbanyak terjadi pada usia 70-79 yaitu 8 orang, dengan rerata pada usia 68 tahun. Nilai PSA yang didapatkan pada dokumen medik antara 8.6-594.41 ng/ml. Uji Spearman yang dilakukan pada penelitian ini diperoleh hasil korelasi yang positif (1-tailed) (koefisien korelasi ( $r$ ) 0.431,  $p < 0.05$ ) antara kadar PSA darah dan ekspresi MMP-2 pada penderita adenokarsinoma prostat. **Simpulan:** Terdapat korelasi positif antara kadar PSA darah dengan ekspresi MMP-2 pada adenokarsinoma prostat.

**Kata Kunci:** Prostate specific antigen, matrix metalloproteinase-2, adenokarsinoma prostat.

Correspondence: Anny Setijo Rahaju; c/o: Department of Anatomic Pathology, Faculty of Medicine/Universitas Airlangga, Soetomo General Hospital Surabaya. Jl. Mayjen. Prof. Dr. Moestopo 6-8 Surabaya 60286. Phone: +62 31 5020251, 5030252, 5030253; Fax: +62 31 5026333. Mobile phone: 081803089442. Email: anny\_setijorahaju@yahoo.com.

## INTRODUCTION

Prostate cancer is a malignancy of the sixth most-common of all types of malignancies in the world, and becomes the second leading cause of

death from cancer in men caused by the incidence of metastasis.<sup>1,2</sup> The incidence of prostate cancer in the United States amounted to about 29% of the incidence of all cancers and 10% of the causes of death.<sup>2,3</sup>



Factors contributing to the clinical application of prostate cancer, among others, are the level of Prostate Specific Antigen (PSA) in serum, Gleason grade, tumor stage, and operation edge.<sup>4</sup> These factors have been studied for the development of molecular prognostic markers in prostate cancer. Some literature suggests that malignant tumor cells produce some matrix that can degrade extracellular matrix (ECM), such as Matrix Metalloproteinase (MMP) family that plays a role in the invasion and metastasis of malignancy.<sup>5</sup>

PSA is produced by prostate gland luminal epithelial cells in the form of ductal and acinar, then secreted into the lumen of the gland and excreted along with semen within the seminal vesicles. In prostate cancer (adenocarcinoma) changes in luminal epithelial cells can penetrate and damage basal cells. Changes in luminal epithelial cells and damage in basal cells cause PSA out of the lumen and come into the blood circulation, resulting in increased concentration of PSA in the blood. The increase can be detected in the blood and used for post-therapy screening and evaluation of prostate cancer.<sup>1,2,6</sup>

Adenocarcinoma is a type of prostate cancer that is most commonly found, and in such malignancy there is an imbalance between MMP and Tissue Inhibitor Metalloproteinase (TIMP), which led the invasion into the surrounding tissue and the incidence of metastasis, both lymphogenic and hematogenous.<sup>7-9</sup> MMP-2 is a member of MMP family that has a special composition and function. MMP-2 (gelatinase A), in its function of invasion and metastasis, degrades collagen IV.<sup>10</sup> The invasion and metastasis that occurs in prostate adenocarcinoma can be assessed from the expression of MMP-2 in tumor cells.<sup>11</sup>

## OBJECTIVE

The aim of this study was to prove the correlation between blood serum PSA level and MMP-2 in prostate adenocarcinoma, since studies on the correlation between blood serum PSA levels and MMP-2 expression in prostate adenocarcinoma is rare.

## MATERIAL & METHODS

This study was an observational analytic study with cross-sectional approach conducted by collecting data from the archive on prostate cancer

patients whose diagnosis was established histopathologically as adenocarcinoma of the prostate in the Department of Pathology, Soetomo General Hospital Surabaya, from January 2009 to May 2012. Data collected were in the form of medical documents of the patients, PSA blood examination and histopathological examination data. Histopathology slides and paraffin blocks of needle biopsies, TURP and Radical Prostatectomy from prostate cancer patients were collected, and then re-reading was done to those cases. Samples taken were patients who had data on blood serum PSA examination by ELISA and met the inclusion criteria. Immunohistochemical staining was done by using MMP-2 antibodies to eligible blocks. Results were obtained by conducting analytical testing with Spearman's correlation by comparing the patients' blood PSA with MMP-2 expression in tumor cells. The study was conducted at the Laboratory of Pathology, Faculty of Medicine, Universitas Airlangga, from May to August 2015.


Immunohistochemical staining on paraffin blocks of patients with a diagnosis of prostate adenocarcinoma was performed using antibodies MMP-2. Assessment of MMP-2 expression was done by assessing the expression in the cytoplasm or tumor cell membrane with staining intensity assessment and the percentage of stained tumor cells. Intensity scores are 0 = tumor cells not stained; 1 = light yellow; 2 = brownish yellow and 3 = brown, while the percentage of cell number is multiplied. The determination of the degree of expression was follows: 0 (negative) when the score is 0; 1+ = 1-3; 2+ = 4-6; and 3+ = 7-9.<sup>12</sup> Data on PSA and MMP-2 expression was tested using Spearman rho correlation test, with significant results if  $p < 0.05$ .

## RESULTS


Data collection was done to obtain data on samples of prostate cancer patients from 2009 to 2012 as many as 22 people in ages of 52-91 years. Prostate adenocarcinoma occurred mostly in the age of 70-79, comprising 8 patients, with a mean age 68 years. PSA values obtained from medical documents were between 8.6 - 594.41 ng/ml.

All samples showed positive MMP-2 expression in the cytoplasm and tumor cells membrane, with the percentage as much as 30-70% and > 70%. The intensity varied from light yellow to brown. Then Spearman tests conducted in this study showed a positive correlation (one-tailed) (correla-

tion coefficient ( $r$ ) 0.431,  $p < 0.05$ ) between blood PSA level and MMP-2 expression in patients with prostate adenocarcinoma.





**Figure 1.** Preparation T. 3045/12, percentage > 70% (3+) and intensity 1 MMP-2 intensity I score +



**Figure 2.** Preparation T. 1662/10 percentage > 70% (3+) and intensity 2.

**Table 1.** MMP-2 expression in prostate adenocarcinoma.

MMP-2 expression score	%	I	score
0	0	0	0
1	0	13	13
2	4	5	5
3	18	4	4
Total	22	22	22



**Figure 3.** Preparation T. 3606/11 and 6324/10 percentage > 70% (3+) and intensity 3.

Blood PSA value in the sample was between 8.6–594.41 ng/ml, showing an increase in serum PSA level. Some literature mentions that the normal level is < 4 ng/ml, showing an increase in blood PSA levels compared to normal.<sup>13,14</sup>

## DISCUSSION

The prostate is a retroperitoneal organ that surrounds the bladder neck and urethra, a gland shaped like a pear. Normal prostate gland is composed of two layers of cells: luminal epithelial cells and basal cells. Secretory/luminal cells have a



function to produce seminal fluid in the form of serine protease (prostate specific antigen/PSA).<sup>1,2</sup> Prostate cancer is most commonly in the form of adenocarcinoma, which is an invasive malignant tumor derived from luminal epithelial cells. In adenocarcinoma luminal epithelial cells change and able to penetrate basal cells, resulting in basal cell damage. Changes in luminal epithelial cells and damage in basal cells cause the produced PSA out of the lumen and enters blood circulation, resulting in increased PSA concentration in blood. The increase can be detected in blood and is used for screening and evaluation of prostate cancer post-treatment as well as indications for biopsy in patients. PSA is also a marker that is often used to diagnose prostate cancer.<sup>1,2,6</sup>

Murray in 2010 also stated that blood PSA value was positively related to the number of malignant epithelial cells stained with immunohistochemical staining with PSA antibody. Increasing number of malignant epithelial cells results in increased blood PSA level, indicating that more malignant cells that damage the barrier will lead to higher levels of PSA detected in the circulation.<sup>14</sup>

The process of cell integrity disruption causes the release of PSA in circulation. This integration disorder also occurs in hyperplasia, inflammation and tumors. PSA value in benign prostate tissue:  $0.5 \pm 0.4$  ng/ml, in BPH:  $0:31 \pm 0:25$  ng/ml, so that up to now there is no definite value in cancer.<sup>6</sup>

Zivkovic in 2004 obtain levels of 4.0-10.0 ng/ml in benign hyperplasia, prostatitis and prostate cancer. Murray conducted a study in 2010 by measuring the weight of prostate tissue, giving results that each gram of prostate cancer tissue can increase PSA of approximately 2.3 ng/ml. Hyperplastic prostate tissue is 10 times lower than cancerous tissue. In addition, they also found that the highest PSA level was in the lumen of the prostate gland, and between gland lumen and capillary blood vessel, basal cells in the gland, prostate stromal and capillary endothelial cells they found barrier that prevents PSA to circulate in the circulation. Therefore, PSA can increase drastically in the state of prostatitis, but can return to normal after the infection resolved.<sup>14</sup>

All samples of this study showed positive expression of MMP-2, according to a study by Trudel (2003), who found that 70% of malignant epithelial cells had positive expression of MMP-2

due to the degradation of ECM by MMP-2.<sup>15</sup> There was a positive correlation between blood PSA levels with MMP-2 expression in prostate cancer, showing that increased blood PSA level is associated with increased MMP-2 expression in prostate cancer (correlation coefficient (r) 0.431,  $p < 0.05$ ).

Malignant cells produce matrix that actively degrades with different specific substrates that act together in the degradation of Extracellular Matrix (ECM), that is the Matrix Metalloproteinase (MMP) family, which is associated with the invasion and metastasis of tumor cells. This tumor metastases is the main cause of death in patients with cancer, particularly prostate cancer.<sup>8,16</sup>

Matrix Metalloproteinase (MMP), or matrix in, is a group of free endopeptidase structure that contain zinc, in cooperation with other proteolysis enzymes, such as cysteine proteinases, aspartic proteinase and serine proteinase, which plays a role in extracellular matrix degradation.<sup>8,9</sup> MMP is secreted in the form of proenzyme, then be activated by the proteolytic gap, and this process can be inhibited by Tissue Inhibitor Metalloproteinase (TIMP) in order to avoid degradation. Imbalance between MMP and TIMP is one of the causes of invasion and metastasis that occurs in malignant tumors.<sup>7-10</sup> Such imbalance is also an important factor that participates in tumor progression.<sup>17</sup> The expression of MMPs (MMP-2 and MMP-9) is often associated with tumor aggressiveness and overall survival, and it is also often used as a marker of malignancy.<sup>18</sup>

Degradation by MMP in malignancy process is taking place through several stages, including: 1) assisting the formation of a micro-environment through the release of extracellular matrix growth factor; 2) assisting the process of tumor angiogenesis, and enhancing the ability of the migration and invasion of tumor cells; 3) playing a role in angiogenesis at the site of metastasis; 4) playing a role in the damage to basal membrane of blood vessel walls, allowing intravasation and extravasation of tumor cells; and 5) playing a role in shaping new microenvironment at metastasis site.<sup>19</sup>

Positive correlation between blood PSA levels with MMP-2 expression in prostate cancer showed that increased blood PSA level is associated with increased MMP-2 expression in prostate cancer (correlation coefficient (r) 0.431,  $p < 0.05$ ). Increased PSA levels in blood indicates barrier damage caused by invasion through the degradation of collagen type IV, as well as damage caused by MMP-2.<sup>20</sup>



According to Amalinei, Caruntu and Balan (2007), based on the substrate specificity, sequence similarity, and domain organization, MMP is divided into 6 groups: gelatinase (MMP-2, MMP-9); matrilysins (MMP-7, MMP-26); collagenases (MMP-1, MMP-8, MMP-13); stromelysin (MMP-3, MMP-10, MMP-11); membrane-type MMP (MT-MMP -> MMP-14, MMP-15, MMP-17, etc.); and other MMPs (MMP-12, MMP-19, etc.).<sup>20</sup>

Gelatinase-type MMP (MMP-2 and MMP-9) plays an important role because it can degrade collagen types IV, V, VII, X, XI, XIV, gelatin, elastin, proteoglycan core proteins, myelin basic protein, fibronectin, fibrillin-1, a precursor TNF-alpha and IL-1b. MMP-2 is able to break down collagen type I, which is the main component that forms the stroma and break down the molecular structure of collagen type IV which is a most protein constituent of basal membrane and the extra cellular matrix, which is instrumental in the invasion process.<sup>7-10</sup> Similarly, Murray in 2009 found that the expression of MMP-2 plays a role in the spread of malignant cells through invasion and metastasis.<sup>14</sup> MMP-2 expression (gelatinase A) in some malignant tumors has been widely studied. This relates to the prognostic value. Studies on the MMP-2 have also been started in prostate cancer (adenocarcinoma).

## CONCLUSION

Blood PSA level correlates positively with MMP-2 expression in prostate adenocarcinoma and increased blood PSA can be used to predict ECM damage in MMP-2-induced prostate adenocarcinoma.

## REFERENCES

- 1 Epstein, JI, Algaba, F, Allbrook, WC, Bastacky, S. Acinar adenocarcinoma, in WHO classification of tumours, pathology and genetics tumours of the urinary system and male genital organs, Ed. Ebk JN, IARC Press, Lyon; 2004. p. 161-92.
- 2 Rosai, J. Male reproductive system. In Rosai and Ackerman's surgical pathology. 9<sup>th</sup> Ed. Elsevier, China. 2011; 1: 1361-87.
- 3 Epstein, JI. The lower urinary tract and male genital system, in Robbins pathologic basic of disease, 8<sup>th</sup> Ed. Saunders: Philadelphia; 2010. p. 993-1003.
- 4 Young, RH. Atlas of tumors pathology, tumors of the prostate gland, seminal vesicles, male uretra, and penis, 3<sup>rd</sup> Series. Armed Forces Institute of Pathology: Washington DC; 2000. p. 111-200.
- 5 Brehmer B, Biesterfeld S, Jakse G. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue, Prostate Cancer and Prostatic Diseases 6; 2003. p. 217-22. doi:10.1038/sj.pcan.4500657.
- 6 <http://emedicine.medscape.com/article/457394-overview>
- 7 Nelson RA, Fingleton B, Rothenberg ML, Matrisian LM, Matrix metalloproteinases: Biologic activity and clinical implications, Journal of Clinical Oncology. 2000; 218(5): 1135-49.
- 8 Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2000; 2(4): 252-7.
- 9 Verma RP, Hansch C. Matrix metalloproteinase (MMPs): chemical-biological function and (Q) SARs. Bioorg Med Chem. 2007; 15(6): 2223-68.
- 10 Tero Leinonen, Risto Pirinen, Jan Bohm. Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer. In Histol Histopathol. 2008; 23: 693-700.
- 11 <http://atlasgeneticsoncology.org/Genes/MMP2ID4136ch16q13.html>
- 12 Daniel Kaemmerer, Luisa Peter, Emelie Lupp. Original Article: Comparing of IRS as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. Int J Clin Exp Pathol. 2012; 5(3): 187-94
- 13 Stadiana Zivkovic. Original article: Correlation between prostate-specific antigen and histopathological difference of prostate carcinoma. In Arch Oncol. 2004; 12(3): 148-51.
- 14 Nigel P. Murray, Gloria M. Calaf, Leonardo Badinez. P504S expressing circulating prostate cells as a marker for prostate cancer. In Oncology Reports. 2010; 24; 687-92.
- 15 Dominique trudel, Yves fradet, Franc. Significance of MMP-2 expression in prostate cancer. An immunohistochemical study. In Cancer research. 2003; 63; 8511-15.
- 16 Yixuan Gong, Uma D. Chippada-Venkata, William K. Oh. Reviews: Roles of matrix metalloproteinase and their natural inhibitors in prostate cancer progression. Cancers. 2014; 6: 1298-327.
- 17 B Brehmer, S Biesterfeld, G Jakse. Prostate cancer and prostatic disease: Expression of matrix metalloproteinase (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue. 2003; 6; 217-22.
- 18 Romano Oguic, Vladimir Mozetic, Eleonora Cini Tesar. Research article: Matrix metalloproteinase 2 and 9 immunoexpression in prostate carcinoma at the positive margin of radical prostatectomy specimen. In Hindawi Publishing Corporation Pathology Research International; 2014. Article ID 262195; 8.
- 19 <http://www.ncbi.nlm.nih.gov/gene/4313>.

20 Amalinei C, Caruntu ID, Balan RA. Biology of metalloproteinases. Romanian Journal of Morpho-

logy and Embryology. 2007; 48(4): 323-34.



## INDONESIAN JOURNAL OF UROLOGY

UNIVERSITAS AIRLANGGA

P-ISSN : 0853442X <> E-ISSN : 23551402 Subject Area : Health

**0.294118**  
Impact Factor

**112**  
Google Citations

**Sinta 2**  
Current Accreditation

- [Google Scholar](#)
- [Garuda](#)
- [Website](#)
- [Editor URL](#)

### History Accreditation



Garuda [Google Scholar](#)

CORRELATION BETWEEN MATERNAL AGE, LOW BIRTH WEIGHT, PREMATURITY AND HORMONAL DRUGS USING WITH THE OCCURRENCE OF HYPOSPADIAS (CASE STUDY AT BINA SEHAT JEMBER HOSPITAL, PARU JEMBER HOSPITAL, AND BHAYANGKARA BONDOWOSO HOSPITAL)

Indonesian Urological Association [Indonesian Journal of Urology Vol 29 No 2 \(2022\)](#)

2022 [DOI: 10.32421/juri.v29i2.452](#) [Accred : Sinta 2](#)



### Journal By Google Scholar

	All	Since 2017
Citation	112	92
h-index	5	4
i10-index	0	0





KEMENTERIAN RISET, TEKNOLOGI, DAN PENDIDIKAN TINGGI  
**DIREKTORAT JENDERAL PENGUATAN RISET  
DAN PENGEMBANGAN**

Jl. M.H. Thamrin No. 8, Jakarta 10340 – Gedung II BPPT, Lantai 20  
Telepon (021) 316-9778. Faksimili (021) 310 1728, 310 2368  
Homepage : [www.ristekdikti.go.id](http://www.ristekdikti.go.id)

Nomor : 1130/E5.2/TU/2016  
Lampiran : satu berkas  
Perihal : Hasil Akreditasi Terbitan Berkala Ilmiah Cetak  
Periode I Tahun 2016

14 Juli 2016

Kepada Yth.

1. Pimpinan Perguruan Tinggi
2. Koordinator Kopertis Wilayah I s.d. XIV
3. Ketua Himpunan Profesi
4. Pengelola Terbitan Berkala Ilmiah di Litbang di seluruh Indonesia

Sehubungan dengan hasil Akreditasi Berkala Ilmiah Cetak Periode I Tahun 2016 dan telah diterbitkannya Surat Keputusan Direktur Jenderal Penguatan Riset dan Pengembangan Kementerian Riset, Teknologi, dan Pendidikan Tinggi Nomor 36a/E/KPT/2016, tanggal 23 Mei 2016, dengan hormat bersama ini kami sampaikan hasil akreditasi sebagaimana terlampir.

Bagi Terbitan Berkala Ilmiah yang terakreditasi akan kami sampaikan Sertifikat Akreditasi.

Guna memantau kualitas Terbitan Berkala Ilmiah, dimohon Saudara dapat mengirimkan 2 eksemplar per terbitan yang ditujukan kepada:

**Direktur Pengelolaan Kekayaan Intelektual,  
Direktorat Pengelolaan Kekayaan Intelektual,  
Kementerian Riset, Teknologi, dan Pendidikan Tinggi  
Up. Kasubdit Fasilitasi Jurnal Ilmiah  
Gedung II Ristek Lantai 20  
Jl. M.H Thamrin No 8, Jakarta 10340**

Atas perhatian dan kerja sama Saudara, kami ucapkan terima kasih.

**Direktur Pengelolaan Kekayaan  
Intelektual**

ttd

**Sadjuga**  
NIP. 195901171986111001

Tembusan:  
Direktur Jenderal Penguatan Riset dan Pengembangan

Lampiran Pengumuman Hasil Akreditasi Terbitan Berkala Ilmiah Cetak Periode I Tahun 2016:

No.	Nama Jurnal	ISSN	Penerbit	Peringkat
1	Episteme: Jurnal Pengembangan Ilmu Keislaman	1907-7491	Pascasarjana dan LP2M Institut Agama Islam Negeri Tulungagung	Terakreditasi B
2	Istinbath	1829-6505	Fakultas Syariah dan Ekonomi Islam IAIN Mataram	Terakreditasi B
3	Asy Syir'ah	0854-8722	Fakultas Syariah dan Hukum UIN Sunan Kalijaga Yogyakarta	Terakreditasi B
4	Esensia: Jurnal Ilmu-Ilmu Ushuluddin	1411-3775	Fakultas Ushuluddin dan Pemikiran Islam UIN Sunan Kalijaga	Terakreditasi B
5	Ahkam: Jurnal Ilmu Syariah	1412-4734	Fakultas Syariah dan Hukum UIN Jakarta	Terakreditasi B
6	Religio: Jurnal Studi Agama-agama	2088-6330	Program Studi Perbandingan Agama Fakultas Ushuluddin UIN Sunan Ampel Surabaya bekerjasama ASAI (Asosiasi Studi Agama Indonesia)	Terakreditasi B
7	Kontekstualita	1979-598X	Puslitpen LP2M IAIN Sulthan Thaha Saifuddin Jambi	Terakreditasi B
8	Konseling Religi: Jurnal Bimbingan Konseling Islam	1907-7238	Program Studi Bimbingan dan Konseling Islam Jurusan Dakwah dan Komunikasi STAIN Kudus	Terakreditasi B
9	Signifikan	2087-2046	Fakultas Ekonomi dan Bisnis, UIN Syarif Hidayatullah Jakarta	Terakreditasi B
10	Jurnal Aplikasi Manajemen (JAM)	1693-5241	Fakultas Ekonomi dan Bisnis UB bekerjasama dengan Asosiasi Ilmuwan Manajemen Indonesia	Terakreditasi B
11	Jurnal Ekonomi Kuantitatif Terapan	2301-8968	Program Studi Ekonomi Pembangunan FEB Universitas Udayana	Terakreditasi B
12	Matrik : Jurnal Manajemen, Strategi Bisnis dan Kewirausahaan	1978-2853	Jurusan Manajemen Fakultas Ekonomi dan Bisnis Universitas Udayana	Terakreditasi B
13	Economic Journal of Emerging Markets	2086-3128	Pusat Pengkajian Ekonomi, Fakultas Ekonomi, Universitas Islam Indonesia Yogyakarta	Terakreditasi B

14	Jurnal Akuntansi dan Auditing Indonesia	1410-2420	Pusat Pengembangan Akuntansi (PPA) Fakultas Ekonomi Universitas Islam Indonesia	Terakreditasi B
15	Jurnal Manajemen dan Kewirausahaan	1411-1438	Program Studi Manajemen, Fakultas Ekonomi Universitas Kristen Petra Surabaya	Terakreditasi B
16	Jurnal Siasat Bisnis	0853-7666	Prodi Manajemen, Fakultas Ekonomi, Universitas Islam Indonesia	Terakreditasi B
17	<i>Journal Of Indonesian Economy And Business (JIEB)</i>	2085-8272	Fakultas Ekonomi dan Bisnis Universitas Gadjah Mada	Terakreditasi B
18	Buletin Ekonomi Moneter dan Perbankan	1410-8046	Bank Indonesia	Terakreditasi B
19	Jurnal Dinamika Manajemen	2086-0668	Jurusan Manajemen, Fakultas Ekonomi Universitas Negeri Semarang bekerjasama dengan AIMI, IFA, dan IMARC	Terakreditasi B
20	<i>Indonesian Capital Market Review</i>	1979-8997	Management Research Center (MRC) FEB UI	Terakreditasi B
21	Jurnal Akuntansi dan Keuangan	1411-0288	Fakultas Ekonomi Program Studi Akuntansi Universitas Kristen Petra Surabaya	Terakreditasi B
22	Iqtishadia	1979-0724	Jurusan Syariah dan Ekonomi Islam STAIN Kudus	Terakreditasi B
23	Jurnal Cita Hukum	2356-1440	Fakultas Syariah dan Hukum UIN Syarif Hidayatullah Jakarta	Terakreditasi B
24	Jurnal Media Hukum	0854-8919	Fakultas Hukum Universitas Muhammadiyah Yogyakarta	Terakreditasi B
25	Berkala Ilmu Kesehatan Kulit dan Kelamin (BIKKK): Periodical of Dermatology and Venereology	1978-4279	Fakultas Kedokteran Universitas Airlangga	Terakreditasi B
26	Paediatrica Indonesiana	0030-9311	Badan Penerbit Ikatan Dokter Anak Indonesia	Terakreditasi B
27	Jurnal Kardiologi Indonesia	0126-3773	Perhimpunan Kardiologi Indonesia	Terakreditasi B
28	<i>Makara Journal of Health Research</i>	2356-3664	Direktorat Riset dan Pengabdian Masyarakat Universitas Indonesia	Terakreditasi B



29	<i>Indonesian Journal of Urology (Jurnal Urologi Indonesia)</i>	0853-442X	Ikatan Ahli Urologi Indonesia (IAUI)	Terakreditasi B
30	<i>Indonesian Journal of Clinical Pathology and Medical Laboratory</i>	0854-4263	Perhimpunan Dokter Spesialis Patologi Klinik Indonesia	Terakreditasi B
31	Jurnal Manajemen dan Pelayanan Farmasi	2088-8139	Prodi S2 Pascasarjana Farmasi UGM	Terakreditasi B
32	Jurnal Pendidikan Usia Dini	1693-1602	Prodi PAUD PPs UNJ dengan Asosiasi Pendidikan Guru PAUD	Terakreditasi B
33	Jurnal Pendidikan Vokasi	2088-2866	Asosiasi Dosen dan Guru Vokasi Indonesia (ADGVI) bekerjasama dengan Program Pascasarjana Universitas Negeri Yogyakarta	Terakreditasi B
34	Teflin Journal	0215-773X	The Association for the Teaching of English as a Foreign Language in Indonesia (TEFLIN)	Terakreditasi A
35	Jurnal Teknologi Pendidikan	1411-2744	Program Studi Teknologi Pendidikan Program Pascasarjana UNJ bekerjasama dengan Ikatan Profesi Teknologi Pendidikan (IPTPI)	Terakreditasi B
36	Jurnal Pengajaran MIPA	1412-0917	Fakultas Pendidikan Matematika dan Ilmu Pengetahuan Alam Universitas Pendidikan Indonesia (FMIPA UPI) dan Perhimpunan Pendidikan IPA Indonesia (PPII)	Terakreditasi B
37	Edukasia: Jurnal Penelitian Pendidikan Islam	1907-7254	Program Studi Pendidikan Agama Islam Jurusan Tarbiyah, STAIN Kudus	Terakreditasi B
38	Omni-Akuatika	1858-3873	Fakultas Perikanan dan Ilmu Kelautan, UNSOED	Terakreditasi B
39	Acta Veterinaria Indonesiana	2337-3202	Fakultas Kedokteran Hewan IPB	Terakreditasi B
40	Jurnal Akuakultur Indonesia	1412-5269	ISSA (Indonesian Society for Scientific Aquaculture)	Terakreditasi B
41	Jurnal Veteriner	1411-8327	Fakultas Kedokteran Hewan, Universitas Udayana bekerjasama dengan Perhimpunan Dokter Hewan Indonesia	Terakreditasi B

42	Buletin Peternakan	0126-4400	Fakultas Peternakan Universitas Gadjah Mada bekerjasama dengan ISSTAP	Terakreditasi B
43	Jurnal Manajemen Hutan Tropika	2087-0469	Departemen Manajemen Hutan, Fakultas Kehutanan Insetitut Pertanian Bogor, Persatuan Sarjana Kehutanan Indonesia (PERSAKI)	Terakreditasi A
44	Jurnal Ilmu Kehutanan	0126-4451	Fakultas Kehutanan UGM dan Persatuan Sarjana Kelautan	Terakreditasi B
45	Jurnal Kedokteran Hewan	1978-225x	Fakultas Kedokteran Hewan Universitas Syiah Kuala	Terakreditasi B
46	Rekam: Jurnal Fotografi, Televisi, Animasi	1858-3997	Asosiasi Dosen Media Rekam (ADSMRI) bekerjasama dengan Fakultas Seni Media Rekam, Institut Seni Indonesia Yogyakarta	Terakreditasi B
47	EL-Harakah	1858-4357	Universitas Islam Negeri (UIN) Maulana Malik Ibrahim Malang	Terakreditasi B
48	Litera	1412-2596	Fakultas Bahasa dan Seni UNY	Terakreditasi B
49	Global & Strategis	1907-9729	Cakra Studi Global dan Strategis (CSGS), Universitas Airlangga	Terakreditasi B
50	Jurnal Ilmu Sosial dan Ilmu Politik (JSP)	1410-4946	Fakultas Ilmu Sosial dan Ilmu Politik UGM	Terakreditasi B
51	Jurnal Komunikasi Aspikom	2087-0442	Asosiasi Perguruan Tinggi Ilmu Komunikasi Bidang Litbang	Terakreditasi B
52	Humanitas - Jurnal Psikologi Indonesia	1693-7236	Fakultas Psikologi, Universitas Ahmad Dahlan	Terakreditasi B
53	Palastren: Jurnal Studi Gender	1979-6056	Pusat Studi Gender STAIN Kudus	Terakreditasi B
54	<i>Makara Human Behaviour Studies in Asia</i>	2355-794X	Direktorat Riset dan Pengabdian Kepada Masyarakat Universitas Indonesia	Terakreditasi B
55	JIK Jurnal Ilmu Komunikasi	1693-3028	Program Studi Ilmu Komunikasi FISIP UPN Veteran Yogyakarta dan Ikatan Sarjana Komunikasi Indonesia (ISKI)	Terakreditasi B
56	Jurnal Ilmu Komunikasi	1829-6564	Program Studi Ilmu Komunikasi, FISIP, Universitas Atma Jaya Yogyakarta	Terakreditasi B



KEMENTERIAN RISET, TEKNOLOGI, DAN PENDIDIKAN TINGGI  
**DIREKTORAT JENDERAL PENGUATAN RISET  
DAN PENGEMBANGAN**

Jl. M.H. Thamrin No. 8, Jakarta 10340 – Gedung II BPPT, Lantai 20  
Telepon (021) 316-9778. Faksimili (021) 310 1728, 310 2368  
Homepage : [www.ristekdikti.go.id](http://www.ristekdikti.go.id)

57	Paramita	0854-0039	Jurusan Sejarah Fakultas Ilmu Sosial Universitas Negeri Semarang dan Masyarakat Sejarawan Indonesia	Terakreditasi A
58	Jurnal Penyuluhan	1858-2664	Program Pascasarjana Ilmu Penyuluhan Pembangunan IPB dan Perhimpunan Ahli Penyuluhan Pembangunan Indonesia	Terakreditasi B
59	Mozaik Humaniora	2442-8469	Unit Penelitian, Publikasi, dan Dokumentasi, Fakultas Ilmu Budaya, Universitas Airlangga	Terakreditasi B
60	K@ta	1411-2639	Program Studi Sastra Inggris, Fakultas Sastra Universitas Kristen Petra Surabaya	Terakreditasi B





**KOMITE ETIK PENELITIAN KESEHATAN  
RSUD Dr. SOETOMO SURABAYA**



**KETERANGAN KELAIKAN ETIK  
(" ETHICAL CLEARANCE ")**

**424 / Panke.KKE / VII / 2017**

**KOMITE ETIK RSUD Dr. SOETOMO SURABAYA TELAH MEMPELAJARI SECARA SEKSAMA RANCANGAN PENELITIAN YANG DIUSULKAN, MAKA DENGAN INI MENYATAKAN BAHWA PENELITIAN DENGAN JUDUL :**

**" Perbandingan Ekspresi MMP-2 dan MMP-9 dengan Kejadian Metastasis Tulang pada Adenokarsinoma Prostat "**

**PENELITI UTAMA : Anny Setijo Rahaju, dr., Sp.PA (K)**

- PENELITI LAIN : 1. Sjahjenny Mustokoweni, dr., Sp.PA (K), MIAC**  
**2. Heriyawati, dr., Sp.PA**  
**3. Aniek Meidy, dr., Sp.PA**  
**4. Dr. Gondo Mastutik, drh., M.Kes**  
**5. Dr. Arifa Mustika, dr., M.Kes**

**UNIT / LEMBAGA / TEMPAT PENELITIAN : RSUD Dr. Soetomo Surabaya**

**DINYATAKAN LAIK ETIK**

**SURABAYA, 4 JUL 2017**  
**KETUA**

**(Dr. Elizeus Hanindito, dr., Sp.An, KIC,KAP)**  
**NIP. 19511007 197903 1 002**



**REDAKSI *INDONESIAN JOURNAL OF UROLOGY***

Kantor Redaksi:  
Departemen/SMF Urologi – RSU Dr. Soetomo Surabaya  
Jl. Mayjend. Prof. Dr. Moestopo No.6-8 Surabaya 60286  
Tel: 62 31 5501318; Fax: 5024971  
Email: indonesianjurol@gmail.com

---

Surabaya, 16<sup>th</sup> April 2016

Anny Setijo Rahaju, Aniek Meidi, Gondo Mastutik, Sjahjenny Mustokoweni, Arifa Mustika:

We have reached a decision regarding your submission to Indonesian Journal of Urology, "Correlation Between Blood Serum Psa Level And Mmp-2 In Prostate Adenocarcinoma".

Our decision is to: Request Revision

-----  
Reviewer A:

Recommendation:

-----

Reviewer Comment

1. The authors should rewrite the article in a more comprehensible language.
  2. The results of their study is not presented clearly.
  3. The authors should dwell on more data such as Gleason score, and progression after treatment because the strength of MMP-2, according to literature, is in prediction of disease progression.
- 

Editor In-Chief,  
*Indonesian Journal of Urology*



**Dr. Tarmono, dr., SpU-K**

## BUKTI KORESPONDENSI

### ARTIKEL JURNAL INTERNASIONAL BEREPUTASI Q3

Judul	Correlation Beetwen Blood Serum PSA Level and MMP-2 in Prostate Adenocarcinoma
Nama Penulis	<b>Anny Setijo Rahaju (Sebagai Penulis Utama dan corresponding author)</b> , Aniek Meidi, Gondo Mastutik, Sjahjenny Mustokowati, Arifa Mustika
Nama Jurnal	Indonesian Journal of Urology Vol. 23 No. 02, July 2016
Penerbit	Ikatan Ahli Urologi Indonesia (IAUI)
26 Januari 2023	Submit Artikel melalui web JURI : <a href="https://juri.urologi.or.id/juri">https://juri.urologi.or.id/juri</a>
Indeks	Accredited No. 158//E/KPT/2021 (Sinta 2) <a href="https://sinta.kemdikbud.go.id/journals/profile/884">https://sinta.kemdikbud.go.id/journals/profile/884</a>
ISSN	0853-442X & E-ISSN 2355-1402
Link artikel	<a href="https://juri.urologi.or.id/juri/article/view/220">https://juri.urologi.or.id/juri/article/view/220</a>
Submitted	25 Oktober 2015
Artikel diterbitkan	20 April 2016
Judul Desertasi dan tahun lulus	MEKANISME ANTI KANKER METFORMIN TERHADAP VIABILITAS SEL KARSINOMA UROTHELIAL KANDUNG KEMIH (CELL LINE 5637) MELALUI miRNA-4257 DAN AMPK 23 November 2021 (tahun lulus)
Bidang Kepekaran	Patologi Ginjal, Saluran Kemih dan Sistem Reproduksi Laki-Laki
Mata Kuliah yang diampu	Pilihan 1 : Patologi Ginjal Pilihan 2 : Patologi Genitalia Pria dan Uropoetika Pilihan 3 : Teknik laboratorium histopatologi dan histokimia

<b>No.</b>	<b>Tanggal</b>	<b>Topik</b>	<b>Hal</b>
1	25 Oktober 2015	Submitted	2
2	2 Agustus 2016	Review Discussion	3
		Editor Decision	4
3	2 Agustus 2016	Copy Editing	5
4	Lampiran	Metadata	6
		Artikel Asli Bahasa Indonesia	7
		Artikel Submission	8
		Artikel After Revisi 1	9
		Artikel After Revisi 2	10
		Published Article	11





### Submissions

[My Queue](#)

[Archives](#)

[Help](#)

### Submissions

#### Archived Submissions



Search

[New Submission](#)

845	<b>Rafael Otniel Kestito, Anny Setijo Rahaju, Tarmono, Abdul K.R. Purba</b> OUTCOMES ANALYSIS OF TRANSURETHRAL RESECTION OF THE PROSTATE (TURP) ...	<span>Published</span>	1	▼
843	<b>Muhamad Abi Salman Aziz, Achmad Fayyad Mas`udi, Anny Setijo Rahaju, Lind...</b> NEW BASELINE GLOMERULAR FILTRATION RATE ESTIMATION AS A GUIDANCE FOR ...	<span>Published</span>	1	▼
220	<b>Anny Setijo Rahaju, Aniek Meidi, Gondo Mastutik, Sjahjenny Mustokoweni, Ar...</b> CORRELATION BETWEEN BLOOD SERUM PSA LEVEL AND MMP-2 IN PROSTATE ADE...	<span>Published</span>	1  1	▲

1	Copiedited files submitted
1	Open discussions

[View Submission](#)

3 of 3 submissions



Submissions

Submission Library

View Metadata

### CORRELATION BETWEEN BLOOD SERUM PSA LEVEL AND MMP-2 IN PROSTATE ADENOCARCINOMA

Anny Setijo Rahaju, Aniek Meidi, Gondo Mastutik, Sjahjenny Mustokowe...

Submission

Review

Copyediting

Production

#### Submission Files

[Search](#)

	469-1	<a href="#">admin, Journal manager, A01 - Correlation between Blood Serum PSA Level.doc</a>	October 25, 2015	Article Text
--	-------	---	------------------	--------------

[Download All Files](#)

#### Pre-Review Discussions

[Add discussion](#)

Name	From	Last Reply	Replies	Closed
<i>No Items</i>				



Submissions

Submission Library

View Metadata

### CORRELATION BETWEEN BLOOD SERUM PSA LEVEL AND MMP-2 IN PROSTATE ADENOCARCINOMA

Anny Setijo Rahaju, Aniek Meidi, Gondo Mastutik, Sjahjenny Mustokowe...

Submission

Review

Copyediting

Production

Round 1

#### Reviewer's Attachments

Search

No Files

#### Revisions

Search

Upload File

No Files

#### Review Discussions

Add discussion

Name	From	Last Reply	Replies	Closed
▶ <a href="#">Editor Decision</a>	anny_setijorahaju19702016-08-02 09:39 AM	-	0	<input type="checkbox"/>

### Editor Decision



#### Participants [Edit](#)

MD,PhD Tarmono Djojodimedjo (tar)

Anny Setijo Rahaju (anny\_setijorahaju1970)

#### Messages

Note	From
Anny Setijo Rahaju: We have reached a decision regarding your submission to Indonesian Journal of Urology, "CORRELATION BETWEEN BLOOD SERUM PSA LEVEL AND MMP-2 IN PROSTATE ADENOCARCINOMA". Our decision is to: admin admin fikririz@gmail.com Indonesian Journal of Urology	anny_setijorahaju19702016-08-02 09:39 AM

Add Message

#### Revisions

No Files

#### Review Discussions

[Add discussion](#)

Name	From	Last Reply	Replies	Closed
<a href="#">▶ Editor Decision</a>	anny_setijorahaju19702016-08-02 09:39 AM	-	0	<input type="checkbox"/>





Submissions

Submission Library

View Metadata

CORRELATION BETWEEN BLOOD SERUM PSA LEVEL AND MMP-2 IN PROSTATE ADENOCARCINOMA

Anny Setijo Rahaju, Aniek Meidi, Gondo Mastutik, Sjahjenny Mustokowe...

Submission

Review

Copyediting

Production

Copyediting Discussions

Add discussion

Name	From	Last Reply	Replies	Closed
<a href="#">Copyediting</a>	—2016-08-03 09:38 AM	-	0	<input type="checkbox"/>

Copyedited

Search

644-1	<a href="#">admin, Journal manager, 220-569-1-ED.doc</a>	August 2, 2016	Article Text
-------	--	-------------------	--------------

**Prefix****Title \***

Examples: A, The

**Subtitle****Abstract \***

**Objective:** This study aims to prove the correlation between Prostate Specific Antigen (PSA) blood level and Matrix Metalloproteinase-2 (MMP-2) expression in patients with prostate adenocarcinoma. **Material & method:** Prostate cancer patients' data from January 2009 to May 2012 were collected at the Department of Pathology, Soetomo General Hospital Surabaya. Data collected included patient medical documents, PSA blood examination, and histopathological examination. Histopathology slides and paraffin blocks of needle biopsies, [Transurethral Resection of Prostate \(TURP\)](#) and radical prostatectomy of prostate cancer patients were re-read, then the samples that met the inclusion criteria were stained by immunohistochemistry using antibodies MMP-2. **Results:** Data collection was done to obtain data

**List of Contributors**

Name	E-mail	Role	Primary Contact	In Browse Lists
Anny Setijo Rahaju	anny_setijorahaju@yahoo.com	Author	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Aniek Meidi	anny_setijorahaju@yahoo.com	Author		<input checked="" type="checkbox"/>
Gondo Mastutik	anny_setijorahaju@yahoo.com	Author		<input checked="" type="checkbox"/>
Sjahjenny Mustokoweni	anny_setijorahaju@yahoo.com	Author		<input checked="" type="checkbox"/>
Arifa Mustika	anny_setijorahaju@yahoo.com	Author		<input checked="" type="checkbox"/>

**Cover Image****Submission Metadata**

These specifications are based on the Dublin Core metadata set, an international standard used to describe journal content.

**Coverage Information****Type**

The submission type is usually one of 'image', 'text', or other multimedia types including 'software' or 'interactive'. Please choose the one most relevant for your submission. Examples may be found at

# Artikel Asli Bahasa Indonesia

## KORELASI ANTARA KADAR PSA SERUM DARAH DENGAN MMP-2 PADA ADENOKARSINOMA PROSTAT

Anny Setijo Rahaju\*, Aniek Meidi\*, Gondo Mastutik\*, Sjahjenny Mustokoweni\*, Arifa Mustika\*\*

\*Departemen Patologi Anatomi, Fakultas Kedokteran Universitas Airlangga

\*\*Departemen Farmakologi, Fakultas Kedokteran Universitas Airlangga

### ABSTRAK

#### Latar Belakang

Kanker prostat merupakan keganasan tersering dan penyebab kematian ke 2 dari semua keganasan pada pria. PSA darah merupakan *tumor marker* yang sering digunakan untuk skrining, karena dapat meningkat pada kanker prostat terutama jenis adenokarsinoma Prostat. Invasi dan metastasis yang terjadi pada adenokarsinoma prostat dapat dinilai dari ekspresi MMP-2 pada sel tumor.

#### Tujuan

Penelitian ini bertujuan untuk membuktikan hubungan antara kadar PSA darah dengan Ekspresi MMP-2 pada penderita Adenokarsinoma Prostat

#### Bahan dan Cara

Penelitian ini mengumpulkan data arsip penderita kanker Prostat yang diagnosisnya ditegakkan secara histopatologik adenokarsinoma prostat di Departemen / SMF / Instalasi Patologi Anatomi RSUD Dr. Soetomo mulai Januari 2009 – Mei 2012. Pengumpulan dokumen medik penderita, data pemeriksaan PSA darah serta data pemeriksaan Histopatologi. Slide Histopatologi dan blok parafin hasil biopsi jarum, TURP dan Radikal Prostatectomy penderita kanker Prostat dibaca ulang, kemudian sample memenuhi kriteria inklusi dipulas secara Imunohistokimia dengan menggunakan antibodi MMP-2. pada Hasil diperoleh dengan melakukan uji analitik dengan Korelasi dari Spearman, dengan membandingkan PSA darah penderita dengan Ekspresi MMP-2 pada sel tumor.

#### Hasil

Pengumpulan data yang dilakukan memperoleh data sample Penderita kanker Prostat pada tahun 2009 sd 2012 sebanyak 22 orang, yang terjadi antara usia 52 - 91 tahun. Adenokarsinoma prostat terbanyak terjadi pada usia 70-79 yaitu 8 orang , dengan rerata pada usia 68 tahun. Nilai PSA yang didapatkan pada dokumen medik antara 8.6 - 594.41 ng/ml.

Semua sample menunjukkan Ekspresi MMP-2 positif pada sitoplasma dan membran sel tumor, dengan prosentase sebanyak 30-70% dan >70 % dan Intensitas yang bervariasi mulai kuning terang sampai dengan coklat. Uji Spearman yang dilakukan pada penelitian ini diperoleh hasil korelasi yang positif (*I-tailed*) (koefisien korelasi (r) 0.431 , $p < 0.05$ ) antara kadar PSA darah dan ekspresi MMP-2 pada penderita adenokarsinoma prostat.

### **Kesimpulan**

Terdapat korelasi positif antara kadar PSA darah dengan ekspresi MMP-2 pada Adenokarsinoma Prostat. serta peningkatan PSA darah dapat digunakan untuk memprediksi kerusakan ECM pada Adenokarsinoma prostat yang disebabkan MMP-2

**Kata Kunci : PSA, MMP-2, Adenokarsinoma Prostat**



## **Pendahuluan**

Kanker Prostat merupakan keganasan terbanyak ke-6 dari semua jenis keganasan didunia dan menjadi penyebab kematian kedua akibat kanker pada pria yang disebabkan karena kejadian metastasis. Di Amerika Serikat, Kanker Prostat berjumlah sekitar 29% dari kejadian semua kanker dan sebanyak 10% menjadi penyebab kematian.

Faktor yang ikut berperan untuk aplikasi klinis penderita kanker Prostat, antara lain : kadar Prostate Spesific Antigen serum, *Gleason grade*, stadium tumor, dan tepi operasi. Faktor-faktor tersebut banyak diteliti untuk pengembangan petanda prognostik molekuler pada kanker Prostat. Beberapa literatur menyatakan sel tumor ganas menghasilkan beberapa matriks, yang dapat mendegradasi Extracelluler Matriks /ECM, antara lain Matrix Metalloproteinase (MMP) family yang berperan dalam invasi dan metastase pada keganasan.

PSA dihasilkan oleh sel epitel luminal kelenjar Prostat yang berupa duktal dan asinar, kemudian disekresikan dalam lumen kelenjar dan dikeluarkan bersama cairan semen di dalam vesikula seminalis. Pada kanker Prostat (Adenokarsinoma) terjadi perubahan pada sel epitel luminal yang dapat menembus sel basal serta terjadi kerusakan pada sel sel basal. Perubahan pada sel epitel Luminal dan kerusakan pada sel Basal menyebabkan PSA yang dihasilkan keluar dari lumen dan masuk dalam sirkulasi darah, sehingga terjadi peningkatan konsentrasi PSA dalam darah. Peningkatan tersebut dapat dideteksi dalam darah dan digunakan untuk skrening dan evaluasi pasca terapi kanker Prostat.

Adenokarsinoma merupakan jenis kanker prostat yang terbanyak ditemukan, dan pada keganasan tersebut terjadi ketidak seimbangan MMP dan Tissue Inhibitor Metalloproteinase (TIMP), yang menyebabkan invasi ke jaringan sekitar dan kejadian metastasis, baik limfogen maupun hematogen. MMP-2 merupakan anggota MMP family yang mempunyai komposisi dan fungsi khusus. MMP-2 (gelatinase A) dalam fungsi invasi dan metastasis, mendegradasi kolagen I dan IV. Invasi dan metastasis yang terjadi pada adenokarsinoma prostat dapat dinilai dari ekspresi MMP-2 pada sel tumor.

Penelitian ini bertujuan untuk membuktikan hubungan kadar PSA serum darah dengan MMP-2 pada Adenokarsinoma Prostat, karena penelitian tentang hubungan kadar PSA serum darah dengan ekspresi MMP-2 pada Adenokarsinoma Prostat masih jarang.

## **Bahan dan Cara**

Penelitian ini merupakan penelitian observasional analitik dengan pendekatan *cross-sectional* yang dilakukan dengan mengumpulkan data arsip penderita kanker Prostat yang diagnosis ditegakkan secara histopatologik adenokarsinoma prostat di Departemen / SMF / Instalasi Patologi Anatomi RSUD Dr. Soetomo mulai Januari 2009 – Mei 2012. Data yang dikumpulkan berupa dokumen medik penderita, data pemeriksaan PSA darah serta data pemeriksaan Histopatologi. Slide Histopatologi dan blok parafin hasil biopsi jarum, TURP dan Radikal Prostatectomy penderita kanker Prostat dikumpulkan, kemudian dilakukan pembacaan ulang pada kasus-kasus tersebut. Sample yang diambil adalah penderita yang memenuhi kriteria inklusi dilakukan pulasan Imunohistokimia dengan menggunakan antibodi MMP-2 pada blok yang memenuhi syarat. Hasil diperoleh dengan melakukan uji analitik dengan Korelasi dari Spearman, dengan membandingkan PSA darah penderita dengan Ekspresi MMP-2 pada sel tumor. Penelitian dilakukan di Laboratorium Patologi Anatomi Fakultas Kedokteran Universitas Airlangga Surabaya pada bulan Mei 2015 sampai dengan Agustus 2015.

## **PSA**

Data diperoleh dari dokumen medik. Penderita yang tidak didapatkan data pemeriksaan PSA dikeluarkan dari sampel penelitian. Pemeriksaan kadar PSA serum darah dilakukan dengan metode ELISA.

## **MMP-2**

Pulasan IHK pada blok parafin penderita dengan diagnosis adenokarsinoma prostat, menggunakan antibodi MMP-2. Penilaian ekspresi MMP-2 dilakukan dengan menilai ekspresi pada sitoplasma atau membran sel tumor dengan penilaian intensitas pewarnaan dan persentase sel tumor yang tercatat. Pemberian score intensitas : 0= bila sel tumor tidak terwarnai; 1=bila kuning terang; 2 = bila kuning kecoklatan dan 3 = bila coklat, sedangkan prosentase jumlah sel dikalikan. Penentuan Derajat Ekspresi sebagai berikut : 0 (negatif) bila score 0; 1+ bila score 1-3; 2+ bila score 4-6; 3+ bila score 7-9.

## **Analisis Data**


Data PSA dan ekspresi MMP-2 yang diperoleh diuji menggunakan uji korelasi dari *spearman' rho*, dengan hasil bermakna jika nilai  $p < 0,05$ .

## Hasil


Pengumpulan data yang dilakukan memperoleh data sample Penderita kanker Prostat pada tahun 2009 sd 2012 sebanyak 22 orang, yang terjadi antara usia 52 - 91 tahun. Adenokarsinoma prostat terbanyak terjadi pada usia 70-79 yaitu 8 orang , dengan rerata pada usia 68 tahun. Nilai PSA yang didapatkan pada dokumen medik antara 8.6 - 594.41 ng/ml.

Semua sample menunjukkan Ekspresi MMP-2 positif pada sitoplasma dan membran sel tumor, dengan prosentase sebanyak 30-70% dan  $>70\%$  dan Intensitas yang bervariasi mulai kuning terang sampai dengan coklat.


Kemudian Uji Spearman yang dilakukan pada penelitian ini diperoleh hasil korelasi yang positif (*1-tailed*) (koefisien korelasi ( $r$ ) 0.431 , $p < 0.05$ ) antara kadar PSA darah dan ekspresi MMP-2 pada penderita adenokarsinoma prostat.



Gambar. 1 Sediaan T. 3045/12 Persentase  $>70\%$ (3+) dan Intensitas 1 MMP-2 Intensitas 1 Score +



Gambar 2. Sediaan T. 1662/10 Persentase >70%(3+) dan Intensitas 2



Gambar 3. Sediaan T. 3606/11 dan 6324/10 Persentase >70%(3+) dan Intensitas 3

Tabel 1. Ekspresi MMP-2 pada Adenokarsinoma Prostat

Skor ekspresi MMP-2	%	I	Skor
0	0	0	0
1	0	13	13
2	4	5	5
3	18	4	4
Total	22	22	22



## Pembahasan

Nilai PSA darah pada sample penelitian diperoleh antara 8.6 - 594.41 ng/ml, menunjukkan peningkatan kadar PSA serum. Beberapa literatur menyebutkan normal adalah <4 ng/ml (Murray, 2010). Hal itu menunjukkan adanya peningkatan kadar PSA darah bila dibanding normal.

Prostat merupakan organ retro peritoneal yang mengelilingi leherbuli dan uretra, berupa kelenjar berbentuk seperti buah pir. Kelenjar Prostat normal terdiri dua lapis sel, yaitu sel epitel luminal dan sel Basal. Sel sekretorik/Luminal berfungsi menghasilkan cairan seminalis berupa serin Protease (*prostate spesific antigen /PSA*). (Epstein,2004; Rosai J., 2011) Kanker Prostat terbanyak berupa Adenokarsinoma, merupakan tumor ganas invasif yang berasal dari sel epitel luminal. Pada Adenokarsinoma terjadi perubahan pada sel epitel luminal yang dapat menembus sel basal serta terjadi kerusakan pada sel sel basal. Perubahan pada sel epitel Luminal dan kerusakan pada sel Basal menyebabkan PSA yang dihasilkan keluar dari lumen dan masuk dalam sirkulasi darah, sehingga terjadi peningkatan konsentrasi PSA dalam darah. Peningkatan tersebut dapat dideteksi dalam darah dan digunakan untuk skrining dan evaluasi pasca terapi kanker Prostat serta indikasi untuk biopsi pada penderita . PSA juga merupakan marker yang sering digunakan untuk menegakkan diagnosis kanker Prostat (Epstein,2004; Rosai J., 2011; Brosman, 2015)

Murray, pada tahun 2009 juga menyatakan nilai PSA darah berhubungan positif dengan jumlah sel epitel ganas yang tercat dengan pulasan IHK dengan antibodi PSA. Apabila jumlah sel epitel ganas meningkat maka nilai PSA darah jugameningkat. Hal tersebut menunjukkan semakin banyak sel ganas yang merusak barrier akan menyebabkan semakin banyakkadar PSA yang terdeteksi dalam sirkulasi. ( Murray,2009)

Proses gangguan integritas sel menyebabkan dilepaskannya PSA dalam sirkulasi, gangguan integrasi ini juga terjadi pada hiperplasi, inflamasi dan tumor. Nilai PSA pada jaringan Prostat jinak :  $0.5 \pm 0.4$  ng/ml, pada BPH :  $0.31 \pm 0.25$  ng/ml, sehingga sampai saat ini belum ada nilai pasti pada kanker. (Brosman, 2015)

Zivcovic mendapatkan hasil kadar 4.0 - 10.0 ng/ml pada Benign hyperplasia, Prostatitis dan kanker prostat. Sedangkan Murray melakukan penelitian dengan mengukur berat jaringan prostat, memberikan hasil tiap gram jaringan kanker prostat dapat meningkatkan PSA sekitar 2.3 ng/ml, jaringan prostat hiperplastik 10 kali lebih rendah

dibanding jaringan kanker. Selain itu juga mendapatkan hasil kadar PSA tertinggi pada lumen kelenjar prostat dan diantara lumen kelenjar dan kapiler pembuluh darah, sel basal pada kelenjar, stroma prostat dan sel endotel kapiler didapatkan barrier yang menghalangi PSA beredar di sirkulasi. Karenanya PSA dapat meningkat secara drastis pada keadaan prostatitis, tetapi dapat kembali normal setelah infeksi teratasi. (Murray, 2009)

Semua sample penelitian ini menunjukkan ekspresi positif pada MMP-2, sesuai Trudel, tahun 2003 memperoleh 70% sel epitel ganas mempunyai ekspresi MMP-2 positif, karena terjadi degradasi ECM oleh MMP-2.

Adanya korelasi positif antara kadar PSA darah dengan ekspresi MMP-2 pada kanker prostat → peningkatan kadar PSA darah berhubungan dengan peningkatan ekspresi MMP-2 pada kanker prostat. (koefisien korelasi (r) 0.431,  $p < 0.05$ )

Sel ganas menghasilkan matriks yang aktif mendegradasi dengan substrat spesifik yang berbeda yang saling bekerjasama dalam degradasi Extracelluler Matriks /ECM, yaitu Matrix Metalloproteinase family (MMP family) yang berhubungan dengan invasi dan metastase sel tumor. Metastase tumor ini merupakan penyebab utama kematian pada pasien kanker terutama kanker Prostat (Duffy MJ, 2000)

*Matrix Metalloproteinase* (MMP) atau *matrixin* merupakan kelompok struktur *endopeptidase* bebas yang mengandung *zinc*, bekerja sama dengan enzim proteolisis lain seperti *cysteine proteinases*, *aspartic proteinases* dan *serine proteinase*, yang berperan dalam degradasi matriks ekstraselular (ECM). (Duffy MJ, 2000, Verma RP & Hansch C, 2007)

MMP disekresi berupa proenzym kemudian diaktifkan oleh adanya celah proteolitik, dan proses ini dapat dihambat oleh *Tissue Inhibitor Metalloproteinase* (TIMP) agar tidak terjadi degradasi. Ketidakseimbangan antara MMP dan TIMP merupakan salah satu penyebab invasi dan metastasis yang terjadi pada tumor ganas.

Degradasi oleh MMP pada proses keganasan, terjadi melalui beberapa tahap, antara lain :

- 1) membantu membentuk microenvironment melalui pelepasan Growth factor matriks ekstraseluler;
- 2) Membantu proses angiogenesis tumor, dan meningkatkan kemampuan migrasi dan invasi sel tumor;
- 3) Berperan pada angiogenesis di lokasi metastasis;
- 4) Berperan dalam kerusakan membran basalis dinding pembuluh darah, memudahkan intravasasi dan ekstravasasi sel tumor;
- 5) Berperan membentuk microenvironment baru ditempat metastasis

Adanya korelasi positif antara kadar PSA darah dengan ekspresi MMP-2 pada kanker prostat menunjukkan peningkatan kadar PSA darah berhubungan dengan peningkatan ekspresi MMP-2 pada kanker prostat. (koefisien korelasi (r) 0.431 , $p < 0.05$ ) Kadar PSA yang meningkat dalam darah menunjukkan adanya kerusakan barrier yang disebabkan invasi melalui degradasi kolagen tipe I dan IV, serta berbagai kerusakan yang ditimbulkan oleh MMP-2.

Menurut Amalinei, Caruntu dan Balan (2007) berdasarkan spesifitas substrat, persamaan rangkaian dan organisasi domain maka MMP dibagi menjadi 6 grup, yaitu :

*Gelatinase* (MMP-2, MMP-9); *matrilysins*, (MMP-7, MMP-26); *collagenases*, (MMP-1, MMP-8, MMP-13); *stromelysin*, (MMP-3, MMP-10, MMP-11); *membran-type* MMP (MT-MMP → MMP-14, MMP-15, MMP-17, dll); MMP lainnya (MMP-12, MMP-19, dll)

MMP jenis gelatinase (MMP-2 dan MMP-9), memegang peranan penting karena mampu mendegradasi kolagen tipe IV, V, VII, X, XI, XIV, gelatin, elastin proteoglycan core protein, myelin basic protein, fibronectin, fibrilin-1, precursor TNF- $\alpha$  dan IL-1b (Stancovic, 2010) MMP-2 mampu memecah kolagen tipe I yang merupakan komponen utama yang membentuk struktur molekul stroma dan memecah kolagen tipe IV merupakan protein penyusun membran basal dan matriks ekstra seluler terbanyak, yang sangat berperan dalam proses invasi. (Stancovic, 2010) Begitu juga Murray pada tahun 2009 menyatakan Ekspresi MMP-2 pada sel ganas berperan dalam penyebaran melalui invasi dan metastasis.

Ekspresi MMP-2 (gelatinase A) pada beberapa tumor ganas telah banyak diteliti, hal ini berkaitan dengan nilai prognostik. Penelitian tentang MMP-2 ini juga mulai diteliti pada kanker (adenokarsinoma) prostat.

## **Kesimpulan dan Saran**

### **Kesimpulan**

1. Terdapat korelasi positif antara kadar PSA darah dengan ekspresi MMP-2 pada Adenokarsinoma Prostat
2. Peningkatan PSA darah dapat digunakan untuk memprediksi kerusakan ECM pada Adenokarsinoma prostat yang disebabkan MMP-2

## **Saran**

1. Dilakukan penelitian lanjutan dengan sampel yang sesuai dengan populasi
2. Kriteria inklusi tentang bone scan dihilangkan
3. Pemeriksaan kadar PSA sebelum dan sesudah tindakan, kemudian ditentukan *cut off* nya
4. Ditambahkan kelompok sample penderita non Neoplasia (BPH dan atau Prostatitis)

## Artikel Submission

### KORELASI ANTARA KADAR PSA SERUM DARAH DENGAN MMP-2 PADA ADENOKARSINOMA PROSTAT

Anny Setijo Rahaju<sup>1</sup>, Aniek Meidi<sup>1</sup>, Gondo Mastutik<sup>1</sup>, Sjahjenny Mustokoweni<sup>1</sup>, Arifa Mustika<sup>2</sup>

<sup>1</sup>Departemen Patologi Anatomi, Fakultas Kedokteran Universitas Airlangga

<sup>2</sup>Departemen Farmakologi, Fakultas Kedokteran Universitas Airlangga

#### ABSTRAK

Kanker prostat merupakan keganasan tersering dan penyebab kematian kedua dari semua keganasan pada pria.<sup>1,2,3</sup> PSA darah merupakan *tumor marker* yang sering digunakan untuk skrining, karena dapat meningkat pada kanker prostat terutama jenis adenokarsinoma Prostat. Invasi dan metastasis yang terjadi pada adenokarsinoma prostat dapat dinilai dari ekspresi MMP-2 pada sel tumor. Penelitian ini bertujuan untuk membuktikan hubungan antara kadar PSA darah dengan Ekspresi MMP-2 pada penderita Adenokarsinoma Prostat. Data arsip penderita kanker Prostat dikumpulkan di Departemen / SMF / Instalasi Patologi Anatomi RSUD Dr. Soetomo mulai Januari 2009-Mei 2012. Pengumpulan data meliputi dokumen medik penderita, data pemeriksaan PSA darah, dan data pemeriksaan Histopatologi. Slide Histopatologi dan blok parafin hasil biopsi jarum, TURP dan Radikal Prostatectomy penderita kanker Prostat dibaca ulang, kemudian sampel memenuhi kriteria inklusi dipulas secara Imunohistokimia dengan menggunakan antibodi MMP-2. Pengumpulan data yang dilakukan memperoleh data sampel Penderita kanker Prostat pada tahun 2009 sampai 2012 sebanyak 22 orang, yang terjadi antara usia 52 - 91 tahun. Adenokarsinoma prostat terbanyak terjadi pada usia 70-79 yaitu 8 orang, dengan rerata pada usia 68 tahun. Nilai PSA yang didapatkan pada dokumen medik antara 8.6 - 594.41 ng/ml. Uji Spearman yang dilakukan pada penelitian ini diperoleh hasil korelasi yang positif (*1-tailed*) (koefisien korelasi (r) 0.431,  $p < 0.05$ ) antara kadar PSA darah dan ekspresi MMP-2 pada penderita adenokarsinoma prostat. Terdapat korelasi positif antara kadar PSA darah dengan ekspresi MMP-2 pada Adenokarsinoma Prostat.

**Kata Kunci : PSA, MMP-2, Adenokarsinoma Prostat**



# **CORRELATION BETWEEN BLOOD SERUM PSA LEVEL AND MMP-2 IN PROSTATE ADENOCARCINOMA**

**Anny Setijo Rahaju<sup>1</sup>, Aniek Meidi<sup>1</sup>, Gondo Mastutik<sup>1</sup>, Sjahjenny Mustokoweni<sup>1</sup>, Arifa Mustika<sup>2</sup>**

<sup>1</sup>Department of Anatomic Pathology, <sup>2</sup>Department of Pharmacology  
Faculty of Medicine, Airlangga University

## **ABSTRACT**

Prostate cancer is the most common malignancy and the second leading cause of death of all malignancies in men. Blood PSA is a tumor marker that is often used for screening, because its level may elevate in prostate cancer, especially prostate adenocarcinoma. Invasion and metastasis that occurs in prostate adenocarcinoma can be assessed from MMP-2 expression in tumor cells. This study aims to prove the correlation between PSA blood level and MMP-2 expression in patients with prostate adenocarcinoma. Prostate cancer patients' data from January 2009 to May 2012 were collected at the Department of Pathology, Dr. Soetomo Hospital. Data collected included patient medical documents, PSA blood examination, and histopathological examination. Histopathology slides and paraffin blocks of needle biopsies, TURP and radical prostatectomy of prostate cancer patients were re-read, then the samples that met the inclusion criteria were stained by immunohistochemistry using antibodies MMP-2. Data collection was done to obtain data samples of prostate cancer patients in 2009 to 2012 comprising as many as 22 patients between the ages of 52-91 years. Prostate adenocarcinoma in age of 70-79 was found in 8 patients, with a mean age of 68 years. PSA values obtained from medical documents were between 8.6 - 594.41 ng/ml. Spearman's test performed in this study showed a positive correlation (one-tailed) (correlation coefficient (r) 0.431,  $p < 0.05$ ) between blood PSA level and MMP-2 expression in patients with prostate adenocarcinoma. Blood PSA level correlates positively with MMP-2 expression in prostate adenocarcinoma.

**Keywords:** PSA, MMP-2, prostate adenocarcinoma

## **INTRODUCTION**

Prostate cancer was a malignancy of the sixth most-common of all types of malignancies in the world, and becomes the second leading cause of death from cancer in men caused by the incidence of metastasis.<sup>1,2</sup> The incidence of prostate cancer in the United States amounted to about 29% of the incidence of all cancers and 10% of the causes of death.<sup>2,3</sup>

There are factors contributing to the clinical application of prostate cancer, among others, are the level of Prostate Specific Antigen (PSA) in serum, Gleason grade, tumor stage, and operation edge.<sup>4</sup> These factors was studied for the development of molecular prognostic markers in prostate cancer. Some literature suggests that malignant tumor cells produce some matrix that can degrade extracellular matrix (ECM), such as Matrix Metalloproteinase (MMP) family that plays a role in the invasion and metastasis of malignancy.<sup>5</sup>

PSA is generated by the luminal epithelial cells of the prostate gland, primarily in the ductal and acinar regions. It is then released into the gland's lumen and expelled with semen through the seminal vesicles. In prostate cancer (adenocarcinoma) changes in luminal epithelial cells can penetrate and damage basal cells. Changes in luminal epithelial cells and damage in basal cells cause PSA out of the lumen and come into the blood circulation, resulting in increased concentration of PSA in the blood. The increase can be detected in the blood and used for post-therapy screening and evaluation of prostate cancer.<sup>1,2,6</sup>

Adenocarcinoma is a type of prostate cancer that is most commonly found, and in such malignancy there is an imbalance between MMP and Tissue Inhibitor Metalloproteinase (TIMP), which led the invasion into the surrounding tissue and the incidence of metastasis, both lymphogenic and hematogenous.<sup>7,8,9</sup> MMP-2 is a member of the MMP family with a unique structure and function. Known as gelatinase A, MMP-2 plays a role in invasion and metastasis by degrading collagen IV. The expression of MMP-2 in tumor cells can be used to assess invasion and metastasis in prostate adenocarcinoma.<sup>11</sup>

## **OBJECTIVE**

The aim of this study was to prove the correlation between blood serum PSA level and MMP-2 in prostate adenocarcinoma, since studies on the correlation between blood serum PSA levels and MMP-2 expression in prostate adenocarcinoma is rare.

## **METHODS**

This study was an observational analytic study with cross-sectional approach conducted by collecting data from the archive on prostate cancer patients whose diagnosis was established histopathologically as adenocarcinoma of the prostate in the Department of Pathology, Dr. Soetomo Hospital, from January 2009 to May 2012. Data collected were in the form of medical documents of the patients, PSA blood examination and histopathological examination data. Histopathology slides and paraffin blocks of needle biopsies, TURP and Radical Prostatectomy from prostate cancer patients were collected, and then re-reading was done to those cases. Samples taken were patients who had data on blood serum PSA examination by ELISA and met the inclusion criteria. Immunohistochemical staining was done by using MMP-2 antibodies to eligible blocks. Results were obtained by conducting analytical testing with Spearman's correlation by comparing the patients' blood PSA with MMP-2 expression in tumor cells. The study was conducted at the Laboratory of Pathology, Faculty of Medicine, Airlangga University, from May to August 2015.

Immunohistochemical staining on paraffin blocks of patients with a diagnosis of prostate adenocarcinoma was performed using antibodies MMP-2. Assessment of MMP-2 expression was done by assessing the expression in the cytoplasm or tumor cell membrane with staining intensity assessment and the percentage of stained tumor cells. Intensity scores are 0 = tumor cells not stained; 1 = light yellow; 2 = brownish yellow and 3 = brown, while the percentage of cell number is multiplied. The determination of the degree of expression was follows: 0 (negative) when the score is 0; 1+ = 1-3; 2+ = 4-6; and 3+ = 7-9.<sup>12</sup> Data on PSA and MMP-2 expression was tested using Spearman 'rho correlation test, with significant results if  $p < 0.05$ .

## RESULTS

Data collection was done to obtain data on samples of prostate cancer patients from 2009 to 2012 as many as 22 people in ages of 52-91 years. Prostate adenocarcinoma occurred mostly in the age of 70-79, comprising 8 patients, with a mean age 68 years. PSA values obtained from medical documents were between 8.6 - 594.41 ng/ml.

All samples showed positive MMP-2 expression in the cytoplasm and tumor cells membrane, with the percentage as much as 30-70% and >70%. The intensity varied from light yellow to brown. Then Spearman tests conducted in this study showed a positive correlation (one-tailed) (correlation coefficient (r) 0.431,  $p < 0.05$ ) between blood PSA level and MMP-2 expression in patients with prostate adenocarcinoma.




Figure 1. Preparation T. 3045/12, percentage >70%(3+) and intensity 1 MMP-2 intensity 1 score +




Figure 2. Preparation T. 1662/10 percentage >70%(3+) and intensity 2




Figure 3. Preparation T. 3606/11 and 6324/10 percentage >70%(3+) and intensity 3

Table 1. MMP-2 expression in prostate adenocarcinoma

MMP-2 expression score	%	I	score
0	0	0	0
1	0	13	13
2	4	5	5
3	18	4	4
Total	22	22	22

Blood PSA value in the sample was between 8.6 - 594.41 ng/ml, showing an increase in serum PSA level. Some literature mentions that the normal level is < 4 ng/ml, showing an increase in blood PSA levels compared to normal.<sup>13,14</sup>

## DISCUSSION

The prostate is a retroperitoneal organ that surrounds the bladder neck and urethra, a gland shaped like a pear. Normal prostate gland is composed of two layers of cells: luminal epithelial cells and basal cells. Secretory/luminal cells have a function to produce seminal fluid in the form of serine protease (prostate specific antigen/PSA).<sup>1,2</sup> Prostate cancer is most commonly in the form of adenocarcinoma, which is an invasive malignant tumor derived from luminal epithelial cells. In adenocarcinoma, luminal epithelial cells undergo changes that enable them to invade basal cells, leading to basal cell damage. These alterations in the luminal epithelial cells and the damage to basal cells cause PSA to leak out of the lumen and into the bloodstream, resulting in elevated PSA levels in the blood. The increase can be detected in blood and is used for screening and evaluation of prostate cancer post-treatment as well as indications for biopsy in patients. PSA is also a marker that is often used to diagnose prostate cancer.<sup>1,2,6</sup>

Murray in 2010 also stated that blood PSA value was positively related to the number of malignant epithelial cells stained with immunohistochemical staining with PSA antibody. Increasing number of malignant epithelial cells results in increased blood PSA level, indicating that more malignant cells that damage the barrier will lead to higher levels of PSA detected in the circulation.<sup>14</sup>

The process of cell integrity disruption causes the release of PSA in circulation. This integration disorder also occurs in hyperplasia, inflammation and tumors. PSA value in benign prostate tissue:  $0.5 \pm 0.4$  ng/ml, in BPH:  $0:31 \pm 0:25$  ng/ml, so that up to now there is no definite value in cancer.<sup>6</sup>

Zivkovic in 2004 obtain levels of 4.0 - 10.0 ng/ml in benign hyperplasia, prostatitis and prostate cancer. Murray conducted a study in 2010 by measuring the weight of prostate tissue, giving results that each gram of prostate cancer tissue can increase PSA of approximately 2.3 ng/ml. The PSA level in hyperplastic prostate tissue is ten times lower than in cancerous tissue. Additionally, it was observed that the highest PSA concentration is found in the lumen of the prostate gland. A barrier exists between the gland's lumen, basal cells, prostate stroma, capillary blood vessels, and capillary endothelial cells, which prevents PSA from entering the bloodstream. Therefore, PSA can increase drastically in the state of prostatitis, but can return to normal after the infection resolved.<sup>14</sup>

All samples of this study showed positive expression of MMP-2, according to a study by Trudel (2003), who found that 70% of malignant epithelial cells had positive expression of MMP-2 due to the degradation of ECM by MMP-2.<sup>15</sup> There was a positive correlation between blood PSA levels with MMP-2 expression in prostate cancer, showing that increased blood PSA level is associated with increased MMP-2 expression in prostate cancer (correlation coefficient (r) 0.431,  $p < 0.05$ ).

Malignant cells produce matrix that actively degrades with different specific substrates that act together in the degradation of Extracellular Matrix (ECM), that is the Matrix



Metalloproteinase (MMP) family, which is associated with the invasion and metastasis of tumor cells. This tumor metastases is the main cause of death in patients with cancer, particularly prostate cancer.<sup>8,16</sup>

Matrix Metalloproteinase (MMP), or matrixin, is a group of free endopeptidase structure that contain zinc, in cooperation with other proteolysis enzymes, such as cysteine proteinases, aspartic proteinase and serine proteinase, which plays a role in extracellular matrix degradation.<sup>8,9</sup> MMP is secreted in the form of proenzyme, then be activated by the proteolytic gap, and this process can be inhibited by Tissue Inhibitor Metalloproteinase (TIMP) in order to avoid degradation. Imbalance between MMP and TIMP is one of the causes of invasion and metastasis that occurs in malignant tumors.<sup>7,8,9,10</sup> Such imbalance is also an important factor that participates in tumor progression.<sup>17</sup> The expression of MMPs (MMP-2 and MMP-9) is often associated with tumor aggressiveness and overall survival, and it is also often used as a marker of malignancy.<sup>18</sup>

Degradation by MMP in malignancy process is taking place through several stages, including: 1) assisting the formation of a microenvironment through the release of extracellular matrix growth factor; 2) assisting the process of tumor angiogenesis, and enhancing the ability of the migration and invasion of tumor cells; 3) playing a role in angiogenesis at the site of metastasis; 4) playing a role in the damage to basal membrane of blood vessel walls, allowing intravasation and extravasation of tumor cells; and 5) playing a role in shaping new microenvironment at metastasis site.<sup>19</sup>

Positive correlation between blood PSA levels with MMP-2 expression in prostate cancer showed that increased blood PSA level is associated with increased MMP-2 expression in prostate cancer (correlation coefficient (r) 0.431,  $p < 0.05$ ). Increased PSA levels in blood indicates barrier damage caused by invasion through the degradation of collagen type IV, as well as damage caused by MMP-2.<sup>20</sup>

According to Amalinei, Caruntu and Balan (2007), based on the substrate specificity, sequence similarity, and domain organization, MMP is divided into 6 groups: gelatinase (MMP-2, MMP-9); matrilysins (MMP-7, MMP-26); collagenases (MMP-1, MMP-8, MMP-13); stromelysin (MMP-3, MMP-10, MMP-11); membrane-type MMP (MT-MMP -> MMP-14, MMP-15, MMP-17, etc.); and other MMPs (MMP-12, MMP-19, etc.).<sup>20</sup>

Gelatinase-type MMP (MMP-2 and MMP-9) plays an important role because it can degrade collagen types IV, V, VII, X, XI, XIV, gelatin, elastin, proteoglycan core proteins, myelin basic protein, fibronectin, fibrillin-1, a precursor TNF-alpha and IL-1b. MMP-2 is able to break down collagen type I, which is the main component that forms the stroma and break down the molecular structure of collagen type IV which is a most protein constituent of basal membrane and the extra cellular matrix, which is instrumental in the invasion process.<sup>7,8,9,10</sup> Similarly, Murray in 2009 found that the expression of MMP-2 plays a role in the spread of malignant cells through invasion and metastasis.<sup>14</sup> MMP-2 expression (gelatinase A) in some malignant tumors has been widely studied. This relates to the prognostic value. Studies on the MMP-2 have also been started in prostate cancer (adenocarcinoma).

## CONCLUSION

There are a correlation between blood PSA level and MMP-2 expression in patients with prostate adenocarcinoma. Blood PSA value in the sample was between 8.6 - 594.41 ng/ml, showing an increase in serum PSA level. Blood PSA level correlates positively with MMP-2 expression in prostate adenocarcinoma, and increased blood PSA can be used to predict ECM damage in MMP-2-induced prostate adenocarcinoma.

## REFERENCES

- 1 Epstein, JI, Algaba, F, Allbrook, WC, Bastacky, S, et al. Acinar adenocarcinoma, in WHO classification of tumours, pathology and genetics tumours of the urinary system and male genital organs, Ed. Etk JN, IARC Press, Lyon. 2004; hh.161- 92.
- 2 Rosai, J. Male reproductive system. in Rosai and Ackerman's surgical pathology. vol.1, 9th ed, Elsevier, China, 2011; hh. 1361-87.
- 3 Epstein, JI. The lower urinary tract and male genital system, in Robbins pathologic basic of disease, 8th ed, Saunders, Philadelphia, 2010; hh. 993-1003.
- 4 Young, RH. Atlas of tumors pathology, tumors of the prostate gland, seminal vesicles, male uretra, and penis, 3rd series, Armed Forces Institute of Pathology, Washington DC, 2000; hh. 111-200.
- 5 Brehmer B, Biesterfeld S, Jakse G. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue, Prostate Cancer and Prostatic Diseases 6, 2003; 217–222. doi:10.1038/sj.pcan.4500657. <http://emedicine.medscape.com/article/457394-overview>
- 6 Nelson RA, Fingleton B, Rothenberg ML, Matrisian LM, Matrix metalloproteinases: Biologic activity and clinical implications, Journal of clinical Oncology, 2000, 218(5):1135-1149.
- 7 Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast cancer res. 2000;2(4):252 - 7.
- 8 Verma RP & Hansch C, Matrix metalloproteinase (MMPs) : chemical-biological function and (Q) SARs; 2007, Bioorg Med Chem 15(6) : 2223-68.
- 9 Tero Leinonen, Risto Pirinen, Jan Bohm, et al. Increased expression of matrix metalloproteinase-2(MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer. In Histol Histopathol; 008; 23: 693-700 <http://atlasgeneticsoncology.org/Genes/MMP2ID41396ch16q13.html>
- 10 Daniel Kaemmerer, Luisa Peter, Emelie Lupp, et al. Original Article: Comparing of IRS as Immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. Int J Clin Exp Pathol ; 2012;5(3):187- 94
- 11 Stadiana Zivkovic. Original article : Correlation between proatate-specific antigen and histopathological difference of prostate carcinoma. In Arch Oncol; 2004; 12(3); 148-51
- 12 Nigel P. Murray, Gloria M. Calaf, Leonardo Badinez, et al. P504S expressing circulating prostate cells as a marker for prostate cancer. In Oncology Reports; 2010; 24; 687-92
- 13 Dominique trudel, Yves fradet, Franc, et al. Significance of mmp-2 expression in prostate cancer. An immunohistochemical study. In Cancer research ; 2003; 63; 8511–15
- 14 Yixuan Gong, Uma D. Chippada-Venkata, William K. Oh. Reviews: Roles of Matrix metalloproteinase and Their Natural Inhibitors in Prostate Cancer Progression. Cancers; 2014; 6 ; 1298-327

- 15 B Brehmer, S Biesterfeld, G Jakse. Prostate Cancer and Prostatic Disease: Expression of matrix metalloproteinase (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue. 2003; 6; 217-22.
- 16 Romano Oguic, Vladimir Mozetic, Eleonora Cini Tesar, et al. Research article: Matrix metalloproteinase 2 and 9 Immunoexpression in Prostate Carcinoma at the positive Margin of Radical Prostatectomy Specimen. In Hindawi Publishing Corporation Pathology Research International ; 2014; Article ID 262195; 8.  
<http://www.ncbi.nlm.nih.gov/gene/4313>
- 17 Amalinei C, Caruntu ID, Balan RA. Biology of metalloproteinases, Romanian Journal of Morphology and Embryology, 2007; 48 (4) : 323-34.
- 18 Stankovic S, Konjevic G, Gopcevic K, Jovic V, Inic M, Jurisic V. Activity of MMP-2 and MMP-9 in sera of breast cancer patients. Pathology - Research and Practice. 2010;206(4):241-7.

# Artikel After Revisi 1

## KORELASI ANTARA KADAR PSA SERUM DARAH DENGAN MMP-2 PADA ADENOKARSINOMA PROSTAT

Anny Setijo Rahaju<sup>1</sup>, Aniek Meidi<sup>1</sup>, Gondo Mastutik<sup>1</sup>, Sjahjenny Mustokoweni<sup>1</sup>, Arifa Mustika<sup>2</sup>

<sup>1</sup>Departemen Patologi Anatomi, Fakultas Kedokteran Universitas Airlangga

<sup>2</sup>Departemen Farmakologi, Fakultas Kedokteran Universitas Airlangga

### ABSTRAK

Kanker prostat merupakan keganasan tersering dan penyebab kematian kedua dari semua keganasan pada pria.<sup>1,2,3</sup> PSA darah merupakan *tumor marker* yang sering digunakan untuk skrining, karena dapat meningkat pada kanker prostat terutama jenis adenokarsinoma Prostat. Invasi dan metastasis yang terjadi pada adenokarsinoma prostat dapat dinilai dari ekspresi MMP-2 pada sel tumor. Penelitian ini bertujuan untuk membuktikan hubungan antara kadar PSA darah dengan Ekspresi MMP-2 pada penderita Adenokarsinoma Prostat. Data arsip penderita kanker Prostat dikumpulkan di Departemen / SMF / Instalasi Patologi Anatomi RSUD Dr. Soetomo mulai Januari 2009-Mei 2012. Pengumpulan data meliputi dokumen medik penderita, data pemeriksaan PSA darah, dan data pemeriksaan Histopatologi. Slide Histopatologi dan blok parafin hasil biopsi jarum, TURP dan Radikal Prostatectomy penderita kanker Prostat dibaca ulang, kemudian sampel memenuhi kriteria inklusi dipulas secara Imunohistokimia dengan menggunakan antibodi MMP-2. Pengumpulan data yang dilakukan memperoleh data sampel Penderita kanker Prostat pada tahun 2009 sampai 2012 sebanyak 22 orang, yang terjadi antara usia 52 - 91 tahun. Adenokarsinoma prostat terbanyak terjadi pada usia 70-79 yaitu 8 orang, dengan rerata pada usia 68 tahun. Nilai PSA yang didapatkan pada dokumen medik antara 8.6 - 594.41 ng/ml. Uji Spearman yang dilakukan pada penelitian ini diperoleh hasil korelasi yang positif (*1-tailed*) (koefisien korelasi (r) 0.431,  $p < 0.05$ ) antara kadar PSA darah dan ekspresi MMP-2 pada penderita adenokarsinoma prostat. Terdapat korelasi positif antara kadar PSA darah dengan ekspresi MMP-2 pada Adenokarsinoma Prostat.

**Kata Kunci : PSA, MMP-2, Adenokarsinoma Prostat**

# **CORRELATION BETWEEN BLOOD SERUM PSA LEVEL AND MMP-2 IN PROSTATE ADENOCARCINOMA**

**Anny Setijo Rahaju<sup>1</sup>, Aniek Meidi<sup>1</sup>, Gondo Mastutik<sup>1</sup>, Sjahjenny Mustokoweni<sup>1</sup>, Arifa Mustika<sup>2</sup>**

<sup>1</sup>Department of Anatomic Pathology, <sup>2</sup>Department of Pharmacology  
Faculty of Medicine, Airlangga University

## **ABSTRACT**

Prostate cancer is the most common malignancy and the second leading cause of death of all malignancies in men. Blood PSA is a tumor marker that is often used for screening, because its level may elevate in prostate cancer, especially prostate adenocarcinoma. Invasion and metastasis that occurs in prostate adenocarcinoma can be assessed from MMP-2 expression in tumor cells. This study aims to prove the correlation between PSA blood level and MMP-2 expression in patients with prostate adenocarcinoma. Prostate cancer patients' data from January 2009 to May 2012 were collected at the Department of Pathology, Dr. Soetomo Hospital. Data collected included patient medical documents, PSA blood examination, and histopathological examination. Histopathology slides and paraffin blocks of needle biopsies, TURP and radical prostatectomy of prostate cancer patients were re-read, then the samples that met the inclusion criteria were stained by immunohistochemistry using antibodies MMP-2. Data collection was done to obtain data samples of prostate cancer patients in 2009 to 2012 comprising as many as 22 patients between the ages of 52-91 years. Prostate adenocarcinoma in age of 70-79 was found in 8 patients, with a mean age of 68 years. PSA values obtained from medical documents were between 8.6 - 594.41 ng/ml. Spearman's test performed in this study showed a positive correlation (one-tailed) (correlation coefficient (r) 0.431,  $p < 0.05$ ) between blood PSA level and MMP-2 expression in patients with prostate adenocarcinoma. Blood PSA level correlates positively with MMP-2 expression in prostate adenocarcinoma.

**Keywords:** PSA, MMP-2, prostate adenocarcinoma

## **INTRODUCTION**

Prostate cancer ~~was~~ is a malignancy of the sixth most-common of all types of malignancies in the world, and becomes the second leading cause of death from cancer in men caused by the incidence of metastasis.<sup>1,2</sup> The incidence of prostate cancer in the United States amounted to about 29% of the incidence of all cancers and 10% of the causes of death.<sup>2,3</sup>

~~There are~~ Factors contributing to the clinical application of prostate cancer, among others, are the level of Prostate Specific Antigen (PSA) in serum, Gleason grade, tumor stage, and operation edge.<sup>4</sup> These factors ~~was~~ have been studied for the development of molecular prognostic markers in prostate cancer. Some literature suggests that malignant tumor cells produce some matrix that can degrade extracellular matrix (ECM), such as Matrix Metalloproteinase (MMP) family that plays a role in the invasion and metastasis of malignancy.<sup>5</sup>



~~PSA is generated by the luminal epithelial cells of the prostate gland, primarily in the ductal and acinar regions. It is then released into the gland's lumen and expelled with semen through the seminal vesicles. PSA is produced by prostate gland luminal epithelial cells in the form of ductal and acinar, then secreted into the lumen of the gland and excreted along with semen within the seminal vesicles. In prostate cancer (adenocarcinoma) changes in luminal epithelial cells can penetrate and damage basal cells. Changes in luminal epithelial cells and damage in basal cells cause PSA out of the lumen and come into the blood circulation, resulting in increased concentration of PSA in the blood. The increase can be detected in the blood and used for post-therapy screening and evaluation of prostate cancer.~~<sup>1,2,6</sup>

Adenocarcinoma is a type of prostate cancer that is most commonly found, and in such malignancy there is an imbalance between MMP and Tissue Inhibitor Metalloproteinase (TIMP), which led the invasion into the surrounding tissue and the incidence of metastasis, both lymphogenic and hematogenous.<sup>7,8,9</sup> ~~MMP-2 is a member of the MMP family with a unique structure and function. Known as gelatinase A, MMP-2 plays a role in invasion and metastasis by degrading collagen IV. The expression of MMP-2 in tumor cells can be used to assess invasion and metastasis in prostate adenocarcinoma.~~ MMP-2 is a member of MMP family that has a special composition and function. MMP-2 (gelatinase A), in its function of invasion and metastasis, degrades collagen IV.<sup>10</sup> The invasion and metastasis that occurs in prostate adenocarcinoma can be assessed from the expression of MMP-2 in tumor cells.<sup>11</sup>

## **OBJECTIVE**

The aim of this study was to prove the correlation between blood serum PSA level and MMP-2 in prostate adenocarcinoma, since studies on the correlation between blood serum PSA levels and MMP-2 expression in prostate adenocarcinoma is rare.

## **METHODS**

This study was an observational analytic study with cross-sectional approach conducted by collecting data from the archive on prostate cancer patients whose diagnosis was established histopathologically as adenocarcinoma of the prostate in the Department of Pathology, Dr. Soetomo Hospital, from January 2009 to May 2012. Data collected were in the form of medical documents of the patients, PSA blood examination and histopathological examination data. Histopathology slides and paraffin blocks of needle biopsies, TURP and Radical Prostatectomy from prostate cancer patients were collected, and then re-reading was done to those cases. Samples taken were patients who had data on blood serum PSA examination by ELISA and met the inclusion criteria. Immunohistochemical staining was done by using MMP-2 antibodies to eligible blocks. Results were obtained by conducting analytical testing with Spearman's correlation by comparing the patients' blood PSA with MMP-2 expression in tumor cells. The study was conducted at the Laboratory of Pathology, Faculty of Medicine, Airlangga University, from May to August 2015.

Immunohistochemical staining on paraffin blocks of patients with a diagnosis of prostate adenocarcinoma was performed using antibodies MMP-2. Assessment of MMP-2 expression was done by assessing the expression in the cytoplasm or tumor cell membrane

with staining intensity assessment and the percentage of stained tumor cells. Intensity scores are 0 = tumor cells not stained; 1 = light yellow; 2 = brownish yellow and 3 = brown, while the percentage of cell number is multiplied. The determination of the degree of expression was follows: 0 (negative) when the score is 0; 1+ = 1-3; 2+ = 4-6; and 3+ = 7-9.<sup>12</sup> Data on PSA and MMP-2 expression was tested using Spearman 'rho correlation test, with significant results if  $p < 0.05$ .

## RESULTS

Data collection was done to obtain data on samples of prostate cancer patients from 2009 to 2012 as many as 22 people in ages of 52-91 years. Prostate adenocarcinoma occurred mostly in the age of 70-79, comprising 8 patients, with a mean age 68 years. PSA values obtained from medical documents were between 8.6 - 594.41 ng/ml.

All samples showed positive MMP-2 expression in the cytoplasm and tumor cells membrane, with the percentage as much as 30-70% and  $>70\%$ . The intensity varied from light yellow to brown. Then Spearman tests conducted in this study showed a positive correlation (one-tailed) (correlation coefficient ( $r$ ) 0.431,  $p < 0.05$ ) between blood PSA level and MMP-2 expression in patients with prostate adenocarcinoma.




Figure 1. Preparation T. 3045/12, percentage  $>70\%$ (3+) and intensity 1 MMP-2 intensity 1 score +





Figure 2. Preparation T. 1662/10 percentage >70%(3+) and intensity 2






Figure 3. Preparation T. 3606/11 and 6324/10 percentage >70%(3+) and intensity 3

Table 1. MMP-2 expression in prostate adenocarcinoma

MMP-2 expression score	%	I	score
0	0	0	0
1	0	13	13
2	4	5	5
3	18	4	4
Total	22	22	22

Blood PSA value in the sample was between 8.6 - 594.41 ng/ml, showing an increase in serum PSA level. Some literature mentions that the normal level is < 4 ng/ml, showing an increase in blood PSA levels compared to normal.<sup>13,14</sup>

## DISCUSSION

The prostate is a retroperitoneal organ that surrounds the bladder neck and urethra, a gland shaped like a pear. Normal prostate gland is composed of two layers of cells: luminal epithelial cells and basal cells. Secretory/luminal cells have a function to produce seminal fluid in the form of serine protease (prostate specific antigen/PSA).<sup>1,2</sup> Prostate cancer is most commonly in the form of adenocarcinoma, which is an invasive malignant tumor derived from luminal epithelial cells. ~~In adenocarcinoma, luminal epithelial cells undergo changes that enable them to invade basal cells, leading to basal cell damage. These alterations in the luminal epithelial cells and the damage to basal cells cause PSA to leak out of the lumen and into the bloodstream, resulting in elevated PSA levels in the blood.~~ In adenocarcinoma luminal epithelial cells change and able to penetrate basal cells, resulting in basal cell damage. Changes in luminal epithelial cells and damage in basal cells cause the produced PSA out of the lumen and enters blood circulation, resulting in increased PSA concentration in blood. The increase can be detected in blood and is used for screening and

evaluation of prostate cancer post-treatment as well as indications for biopsy in patients. PSA is also a marker that is often used to diagnose prostate cancer.<sup>1,2,6</sup>

Murray in 2010 also stated that blood PSA value was positively related to the number of malignant epithelial cells stained with immunohistochemical staining with PSA antibody. Increasing number of malignant epithelial cells results in increased blood PSA level, indicating that more malignant cells that damage the barrier will lead to higher levels of PSA detected in the circulation.<sup>14</sup>

The process of cell integrity disruption causes the release of PSA in circulation. This integration disorder also occurs in hyperplasia, inflammation and tumors. PSA value in benign prostate tissue:  $0.5 \pm 0.4$  ng/ml, in BPH:  $0.31 \pm 0.25$  ng/ml, so that up to now there is no definite value in cancer.<sup>6</sup>

Zivkovic in 2004 obtain levels of 4.0 - 10.0 ng/ml in benign hyperplasia, prostatitis and prostate cancer. Murray conducted a study in 2010 by measuring the weight of prostate tissue, giving results that each gram of prostate cancer tissue can increase PSA of approximately 2.3 ng/ml. ~~The PSA level in hyperplastic prostate tissue is ten times lower than in cancerous tissue. Additionally, it was observed that the highest PSA concentration is found in the lumen of the prostate gland. A barrier exists between the gland's lumen, basal cells, prostate stroma, capillary blood vessels, and capillary endothelial cells, which prevents PSA from entering the bloodstream.~~ Hyperplastic prostate tissue is 10 times lower than cancerous tissue. In addition, they also found that the highest PSA level was in the lumen of the prostate gland, and between gland lumen and capillary blood vessel, basal cells in the gland, prostate stromal and capillary endothelial cells they found barrier that prevents PSA to circulate in the circulation. Therefore, PSA can increase drastically in the state of prostatitis, but can return to normal after the infection resolved.<sup>14</sup>

All samples of this study showed positive expression of MMP-2, according to a study by Trudel (2003), who found that 70% of malignant epithelial cells had positive expression of MMP-2 due to the degradation of ECM by MMP-2.<sup>15</sup> There was a positive correlation between blood PSA levels with MMP-2 expression in prostate cancer, showing that increased blood PSA level is associated with increased MMP-2 expression in prostate cancer (correlation coefficient (r) 0.431,  $p < 0.05$ ).

Malignant cells produce matrix that actively degrades with different specific substrates that act together in the degradation of Extracellular Matrix (ECM), that is the Matrix Metalloproteinase (MMP) family, which is associated with the invasion and metastasis of tumor cells. This tumor metastases is the main cause of death in patients with cancer, particularly prostate cancer.<sup>8,16</sup>

Matrix Metalloproteinase (MMP), or matrixin, is a group of free endopeptidase structure that contain zinc, in cooperation with other proteolysis enzymes, such as cysteine proteinases, aspartic proteinase and serine proteinase, which plays a role in extracellular matrix degradation.<sup>8,9</sup> MMP is secreted in the form of proenzyme, then be activated by the proteolytic gap, and this process can be inhibited by Tissue Inhibitor Metalloproteinase (TIMP) in order to avoid degradation. Imbalance between MMP and TIMP is one of the causes of invasion and metastasis that occurs in malignant tumors.<sup>7,8,9,10</sup> Such imbalance is also an important factor that participates in tumor progression.<sup>17</sup> The expression of MMPs



(MMP-2 and MMP-9) is often associated with tumor aggressiveness and overall survival, and it is also often used as a marker of malignancy.<sup>18</sup>

Degradation by MMP in malignancy process is taking place through several stages, including: 1) assisting the formation of a microenvironment through the release of extracellular matrix growth factor; 2) assisting the process of tumor angiogenesis, and enhancing the ability of the migration and invasion of tumor cells; 3) playing a role in angiogenesis at the site of metastasis; 4) playing a role in the damage to basal membrane of blood vessel walls, allowing intravasation and extravasation of tumor cells; and 5) playing a role in shaping new microenvironment at metastasis site.<sup>19</sup>

Positive correlation between blood PSA levels with MMP-2 expression in prostate cancer showed that increased blood PSA level is associated with increased MMP-2 expression in prostate cancer (correlation coefficient (r) 0.431,  $p < 0.05$ ). Increased PSA levels in blood indicates barrier damage caused by invasion through the degradation of collagen type IV, as well as damage caused by MMP-2.<sup>20</sup>

According to Amalinei, Caruntu and Balan (2007), based on the substrate specificity, sequence similarity, and domain organization, MMP is divided into 6 groups: gelatinase (MMP-2, MMP-9); matrilysins (MMP-7, MMP-26); collagenases (MMP-1, MMP-8, MMP-13); stromelysin (MMP-3, MMP-10, MMP-11); membrane-type MMP (MT-MMP → MMP-14, MMP-15, MMP-17, etc.); and other MMPs (MMP-12, MMP-19, etc.).<sup>20</sup> In addition, the Gleason score is used to assess the tumor grading. It consists of 5 tiered scores ranging from 6 to 10.

Gelatinase-type MMP (MMP-2 and MMP-9) plays an important role because it can degrade collagen types IV, V, VII, X, XI, XIV, gelatin, elastin, proteoglycan core proteins, myelin basic protein, fibronectin, fibrillin-1, a precursor TNF-alpha and IL-1b. MMP-2 is able to break down collagen type I, which is the main component that forms the stroma and break down the molecular structure of collagen type IV which is a most protein constituent of basal membrane and the extra cellular matrix, which is instrumental in the invasion process.<sup>7,8,9,10</sup> Similarly, Murray in 2009 found that the expression of MMP-2 plays a role in the spread of malignant cells through invasion and metastasis.<sup>14</sup> MMP-2 expression (gelatinase A) in some malignant tumors has been widely studied. This relates to the prognostic value. Studies on the MMP-2 have also been started in prostate cancer (adenocarcinoma).

## CONCLUSION

~~There are a correlation between blood PSA level and MMP-2 expression in patients with prostate adenocarcinoma. Blood PSA value in the sample was between 8.6—594.41 ng/ml, showing an increase in serum PSA level.~~ Blood PSA level correlates positively with MMP-2 expression in prostate adenocarcinoma, and increased blood PSA can be used to predict ECM damage in MMP-2-induced prostate adenocarcinoma.

## REFERENCES

- 1 Epstein, JI, Algaba, F, Allbrook, WC, Bastacky, S, et al. Acinar adenocarcinoma, in WHO classification of tumours, pathology and genetics tumours of the urinary system and male genital organs, Ed. Etk JN, IARC Press, Lyon. 2004; hh.161- 92.
- 2 Rosai, J. Male reproductive system. in Rosai and Ackerman's surgical pathology. vol.1, 9th ed, Elsevier, China, 2011; hh. 1361-87.
- 3 Epstein, JI. The lower urinary tract and male genital system, in Robbins pathologic basic of disease, 8th ed, Saunders, Philadelphia, 2010; hh. 993-1003.
- 4 Young, RH. Atlas of tumors pathology, tumors of the prostate gland, seminal vesicles, male uretra, and penis, 3rd series, Armed Forces Institute of Pathology, Washington DC, 2000; hh. 111-200.
- 5 Brehmer B, Biesterfeld S, Jakse G. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue, Prostate Cancer and Prostatic Diseases 6, 2003; 217–222. doi:10.1038/sj.pcan.4500657.  
<http://emedicine.medscape.com/article/457394-overview>
- 6 Nelson RA, Fingleton B, Rothenberg ML, Matrisian LM, Matrix metalloproteinases: Biologic activity and clinical implications, Journal of clinical Oncology, 2000, 218(5):1135-1149.
- 7 Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast cancer res. 2000;2(4):252 - 7.
- 8 Verma RP & Hansch C, Matrix metalloproteinase (MMPs) : chemical-biological function and (Q) SARs; 2007, Bioorg Med Chem 15(6) : 2223-68.
- 9 Tero Leinonen, Risto Pirinen, Jan Bohm, et al. Increased expression of matrix metalloproteinase-2(MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer. In Histol Histopathol; 008; 23: 693-700  
<http://atlasgeneticsoncology.org/Genes/MMP2ID41396ch16q13.html>
- 10 Daniel Kaemmerer, Luisa Peter, Emelie Lupp, et al. Original Article: Comparing of IRS as Immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. Int J Clin Exp Pathol ; 2012;5(3):187- 94
- 11 Stadiana Zivkovic. Original article : Correlation between proatate-specific antigen and histopathological difference of prostate carcinoma. In Arch Oncol; 2004; 12(3); 148-51
- 12 Nigel P. Murray, Gloria M. Calaf, Leonardo Badinez, et al. P504S expressing circulating prostate cells as a marker for prostate cancer. In Oncology Reports; 2010; 24; 687-92
- 13 Dominique trudel, Yves fradet, Franc, et al. Significance of mmp-2 expression in prostate cancer. An immunohistochemical study. In Cancer research ; 2003; 63; 8511–15
- 14 Yixuan Gong, Uma D. Chippada-Venkata, William K. Oh. Reviews: Roles of Matrix metalloproteinase and Their Natural Inhibitors in Prostate Cancer Progression. Cancers; 2014; 6 ; 1298-327
- 15 B Brehmer, S Biesterfeld, G Jakse. Prostate Cancer and Prostatic Disease: Expression of matrix metalloproteinase (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue. 2003; 6; 217-22.
- 16 Romano Oguic, Vladimir Mozetic, Eleonora Cini Tesar, et al. Research article: Matrix metalloproteinase 2 and 9 Immunoexpression in Prostate Carcinoma at the positive Margin of Radical Prostatectomy Specimen. In Hindawi Publishing Corporation Pathology Research International ; 2014; Article ID 262195; 8.  
<http://www.ncbi.nlm.nih.gov/gene/4313>
- 17 Amalinei C, Caruntu ID, Balan RA. Biology of metalloproteinases, Romanian Journal of Morphology and Embryology, 2007; 48 (4) : 323-34.

- 18 Stankovic S, Konjevic G, Gopcevic K, Jovic V, Inic M, Jurisic V. Activity of MMP-2 and MMP-9 in sera of breast cancer patients. *Pathology - Research and Practice*. 2010;206(4):241-7.

## Artikel After Revisi 2

### KORELASI ANTARA KADAR PSA SERUM DARAH DENGAN MMP-2 PADA ADENOKARSINOMA PROSTAT

Anny Setijo Rahaju<sup>1</sup>, Aniek Meidi<sup>1</sup>, Gondo Mastutik<sup>1</sup>, Sjahjenny Mustokoweni<sup>1</sup>, Arifa Mustika<sup>2</sup>

<sup>1</sup>Departemen Patologi Anatomi, Fakultas Kedokteran Universitas Airlangga

<sup>2</sup>Departemen Farmakologi, Fakultas Kedokteran Universitas Airlangga

#### ABSTRAK

Kanker prostat merupakan keganasan tersering dan penyebab kematian kedua dari semua keganasan pada pria.<sup>1,2,3</sup> PSA darah merupakan *tumor marker* yang sering digunakan untuk skrining, karena dapat meningkat pada kanker prostat terutama jenis adenokarsinoma Prostat. Invasi dan metastasis yang terjadi pada adenokarsinoma prostat dapat dinilai dari ekspresi MMP-2 pada sel tumor. Penelitian ini bertujuan untuk membuktikan hubungan antara kadar PSA darah dengan Ekspresi MMP-2 pada penderita Adenokarsinoma Prostat. Data arsip penderita kanker Prostat dikumpulkan di Departemen / SMF / Instalasi Patologi Anatomi RSUD Dr. Soetomo mulai Januari 2009-Mei 2012. Pengumpulan data meliputi dokumen medik penderita, data pemeriksaan PSA darah, dan data pemeriksaan Histopatologi. Slide Histopatologi dan blok parafin hasil biopsi jarum, TURP dan Radikal Prostatectomy penderita kanker Prostat dibaca ulang, kemudian sampel memenuhi kriteria inklusi dipulas secara Imunohistokimia dengan menggunakan antibodi MMP-2. Pengumpulan data yang dilakukan memperoleh data sampel Penderita kanker Prostat pada tahun 2009 sampai 2012 sebanyak 22 orang, yang terjadi antara usia 52 - 91 tahun. Adenokarsinoma prostat terbanyak terjadi pada usia 70-79 yaitu 8 orang, dengan rerata pada usia 68 tahun. Nilai PSA yang didapatkan pada dokumen medik antara 8.6 - 594.41 ng/ml. Uji Spearman yang dilakukan pada penelitian ini diperoleh hasil korelasi yang positif (*1-tailed*) (koefisien korelasi (r) 0.431,  $p < 0.05$ ) antara kadar PSA darah dan ekspresi MMP-2 pada penderita adenokarsinoma prostat. Terdapat korelasi positif antara kadar PSA darah dengan ekspresi MMP-2 pada Adenokarsinoma Prostat.

**Kata Kunci : PSA, MMP-2, Adenokarsinoma Prostat**

# **CORRELATION BETWEEN BLOOD SERUM PSA LEVEL AND MMP-2 IN PROSTATE ADENOCARCINOMA**

**Anny Setijo Rahaju<sup>1</sup>, Aniek Meidi<sup>1</sup>, Gondo Mastutik<sup>1</sup>, Sjahjenny Mustokoweni<sup>1</sup>, Arifa Mustika<sup>2</sup>**

<sup>1</sup>Department of Anatomic Pathology, <sup>2</sup>Department of Pharmacology  
Faculty of Medicine, Airlangga University

## **ABSTRACT**

Prostate cancer is the most common malignancy and the second leading cause of death of all malignancies in men. Blood PSA is a tumor marker that is often used for screening, because its level may elevate in prostate cancer, especially prostate adenocarcinoma. Invasion and metastasis that occurs in prostate adenocarcinoma can be assessed from MMP-2 expression in tumor cells. This study aims to prove the correlation between PSA blood level and MMP-2 expression in patients with prostate adenocarcinoma. Prostate cancer patients' data from January 2009 to May 2012 were collected at the Department of Pathology, Dr. Soetomo Hospital. Data collected included patient medical documents, PSA blood examination, and histopathological examination. Histopathology slides and paraffin blocks of needle biopsies, TURP and radical prostatectomy of prostate cancer patients were re-read, then the samples that met the inclusion criteria were stained by immunohistochemistry using antibodies MMP-2. Data collection was done to obtain data samples of prostate cancer patients in 2009 to 2012 comprising as many as 22 patients between the ages of 52-91 years. Prostate adenocarcinoma in age of 70-79 was found in 8 patients, with a mean age of 68 years. PSA values obtained from medical documents were between 8.6 - 594.41 ng/ml. Spearman's test performed in this study showed a positive correlation (one-tailed) (correlation coefficient (r) 0.431,  $p < 0.05$ ) between blood PSA level and MMP-2 expression in patients with prostate adenocarcinoma. Blood PSA level correlates positively with MMP-2 expression in prostate adenocarcinoma.

**Keywords:** PSA, MMP-2, prostate adenocarcinoma

## **INTRODUCTION**

Prostate cancer ~~was~~ is a malignancy of the sixth most-common of all types of malignancies in the world, and becomes the second leading cause of death from cancer in men caused by the incidence of metastasis.<sup>1,2</sup> The incidence of prostate cancer in the United States amounted to about 29% of the incidence of all cancers and 10% of the causes of death.<sup>2,3</sup>

~~There are~~ Factors contributing to the clinical application of prostate cancer, among others, are the level of Prostate Specific Antigen (PSA) in serum, Gleason grade, tumor stage, and operation edge.<sup>4</sup> These factors ~~was~~ have been studied for the development of molecular prognostic markers in prostate cancer. Some literature suggests that malignant tumor cells produce some matrix that can degrade extracellular matrix (ECM), such as Matrix Metalloproteinase (MMP) family that plays a role in the invasion and metastasis of malignancy.<sup>5</sup>



~~PSA is generated by the luminal epithelial cells of the prostate gland, primarily in the ductal and acinar regions. It is then released into the gland's lumen and expelled with semen through the seminal vesicles. PSA is produced by prostate gland luminal epithelial cells in the form of ductal and acinar, then secreted into the lumen of the gland and excreted along with semen within the seminal vesicles. In prostate cancer (adenocarcinoma) changes in luminal epithelial cells can penetrate and damage basal cells. Changes in luminal epithelial cells and damage in basal cells cause PSA out of the lumen and come into the blood circulation, resulting in increased concentration of PSA in the blood. The increase can be detected in the blood and used for post-therapy screening and evaluation of prostate cancer.~~<sup>1,2,6</sup>

Adenocarcinoma is a type of prostate cancer that is most commonly found, and in such malignancy there is an imbalance between MMP and Tissue Inhibitor Metalloproteinase (TIMP), which led the invasion into the surrounding tissue and the incidence of metastasis, both lymphogenic and hematogenous.<sup>7,8,9</sup> ~~MMP-2 is a member of the MMP family with a unique structure and function. Known as gelatinase A, MMP-2 plays a role in invasion and metastasis by degrading collagen IV. The expression of MMP-2 in tumor cells can be used to assess invasion and metastasis in prostate adenocarcinoma.~~ MMP-2 is a member of MMP family that has a special composition and function. MMP-2 (gelatinase A), in its function of invasion and metastasis, degrades collagen IV.<sup>10</sup> The invasion and metastasis that occurs in prostate adenocarcinoma can be assessed from the expression of MMP-2 in tumor cells.<sup>11</sup>

## **OBJECTIVE**

The aim of this study was to prove the correlation between blood serum PSA level and MMP-2 in prostate adenocarcinoma, since studies on the correlation between blood serum PSA levels and MMP-2 expression in prostate adenocarcinoma is rare.

## **METHODS**

This study was an observational analytic study with cross-sectional approach conducted by collecting data from the archive on prostate cancer patients whose diagnosis was established histopathologically as adenocarcinoma of the prostate in the Department of Pathology, Dr. Soetomo Hospital, from January 2009 to May 2012. Data collected were in the form of medical documents of the patients, PSA blood examination and histopathological examination data. Histopathology slides and paraffin blocks of needle biopsies, TURP and Radical Prostatectomy from prostate cancer patients were collected, and then re-reading was done to those cases. Samples taken were patients who had data on blood serum PSA examination by ELISA and met the inclusion criteria. Immunohistochemical staining was done by using MMP-2 antibodies to eligible blocks. Results were obtained by conducting analytical testing with Spearman's correlation by comparing the patients' blood PSA with MMP-2 expression in tumor cells. The study was conducted at the Laboratory of Pathology, Faculty of Medicine, Airlangga University, from May to August 2015.

Immunohistochemical staining on paraffin blocks of patients with a diagnosis of prostate adenocarcinoma was performed using antibodies MMP-2. Assessment of MMP-2 expression was done by assessing the expression in the cytoplasm or tumor cell membrane

with staining intensity assessment and the percentage of stained tumor cells. Intensity scores are 0 = tumor cells not stained; 1 = light yellow; 2 = brownish yellow and 3 = brown, while the percentage of cell number is multiplied. The determination of the degree of expression was follows: 0 (negative) when the score is 0; 1+ = 1-3; 2+ = 4-6; and 3+ = 7-9.<sup>12</sup> Data on PSA and MMP-2 expression was tested using Spearman 'rho correlation test, with significant results if  $p < 0.05$ .

## RESULTS

Data collection was done to obtain data on samples of prostate cancer patients from 2009 to 2012 as many as 22 people in ages of 52-91 years. Prostate adenocarcinoma occurred mostly in the age of 70-79, comprising 8 patients, with a mean age 68 years. PSA values obtained from medical documents were between 8.6 - 594.41 ng/ml.

All samples showed positive MMP-2 expression in the cytoplasm and tumor cells membrane, with the percentage as much as 30-70% and  $>70\%$ . The intensity varied from light yellow to brown. Then Spearman tests conducted in this study showed a positive correlation (one-tailed) (correlation coefficient ( $r$ ) 0.431,  $p < 0.05$ ) between blood PSA level and MMP-2 expression in patients with prostate adenocarcinoma.




Figure 1. Preparation T. 3045/12, percentage  $>70\%$ (3+) and intensity 1 MMP-2 intensity 1 score +





Figure 2. Preparation T. 1662/10 percentage >70%(3+) and intensity 2






Figure 3. Preparation T. 3606/11 and 6324/10 percentage >70%(3+) and intensity 3

Table 1. MMP-2 expression in prostate adenocarcinoma

MMP-2 expression score	%	I	score
0	0	0	0
1	0	13	13
2	4	5	5
3	18	4	4
Total	22	22	22

Blood PSA value in the sample was between 8.6 - 594.41 ng/ml, showing an increase in serum PSA level. Some literature mentions that the normal level is < 4 ng/ml, showing an increase in blood PSA levels compared to normal.<sup>13,14</sup>

## DISCUSSION

The prostate is a retroperitoneal organ that surrounds the bladder neck and urethra, a gland shaped like a pear. Normal prostate gland is composed of two layers of cells: luminal epithelial cells and basal cells. Secretory/luminal cells have a function to produce seminal fluid in the form of serine protease (prostate specific antigen/PSA).<sup>1,2</sup> Prostate cancer is most commonly in the form of adenocarcinoma, which is an invasive malignant tumor derived from luminal epithelial cells. ~~In adenocarcinoma, luminal epithelial cells undergo changes that enable them to invade basal cells, leading to basal cell damage. These alterations in the luminal epithelial cells and the damage to basal cells cause PSA to leak out of the lumen and into the bloodstream, resulting in elevated PSA levels in the blood.~~ In adenocarcinoma luminal epithelial cells change and able to penetrate basal cells, resulting in basal cell damage. Changes in luminal epithelial cells and damage in basal cells cause the produced PSA out of the lumen and enters blood circulation, resulting in increased PSA concentration in blood. The increase can be detected in blood and is used for screening and

evaluation of prostate cancer post-treatment as well as indications for biopsy in patients. PSA is also a marker that is often used to diagnose prostate cancer.<sup>1,2,6</sup>

Murray in 2010 also stated that blood PSA value was positively related to the number of malignant epithelial cells stained with immunohistochemical staining with PSA antibody. Increasing number of malignant epithelial cells results in increased blood PSA level, indicating that more malignant cells that damage the barrier will lead to higher levels of PSA detected in the circulation.<sup>14</sup>

The process of cell integrity disruption causes the release of PSA in circulation. This integration disorder also occurs in hyperplasia, inflammation and tumors. PSA value in benign prostate tissue:  $0.5 \pm 0.4$  ng/ml, in BPH:  $0.31 \pm 0.25$  ng/ml, so that up to now there is no definite value in cancer.<sup>6</sup>

Zivkovic in 2004 obtain levels of 4.0 - 10.0 ng/ml in benign hyperplasia, prostatitis and prostate cancer. Murray conducted a study in 2010 by measuring the weight of prostate tissue, giving results that each gram of prostate cancer tissue can increase PSA of approximately 2.3 ng/ml. ~~The PSA level in hyperplastic prostate tissue is ten times lower than in cancerous tissue. Additionally, it was observed that the highest PSA concentration is found in the lumen of the prostate gland. A barrier exists between the gland's lumen, basal cells, prostate stroma, capillary blood vessels, and capillary endothelial cells, which prevents PSA from entering the bloodstream.~~ Hyperplastic prostate tissue is 10 times lower than cancerous tissue. In addition, they also found that the highest PSA level was in the lumen of the prostate gland, and between gland lumen and capillary blood vessel, basal cells in the gland, prostate stromal and capillary endothelial cells they found barrier that prevents PSA to circulate in the circulation. Therefore, PSA can increase drastically in the state of prostatitis, but can return to normal after the infection resolved.<sup>14</sup>

All samples of this study showed positive expression of MMP-2, according to a study by Trudel (2003), who found that 70% of malignant epithelial cells had positive expression of MMP-2 due to the degradation of ECM by MMP-2.<sup>15</sup> There was a positive correlation between blood PSA levels with MMP-2 expression in prostate cancer, showing that increased blood PSA level is associated with increased MMP-2 expression in prostate cancer (correlation coefficient (r) 0.431,  $p < 0.05$ ).

Malignant cells produce matrix that actively degrades with different specific substrates that act together in the degradation of Extracellular Matrix (ECM), that is the Matrix Metalloproteinase (MMP) family, which is associated with the invasion and metastasis of tumor cells. This tumor metastases is the main cause of death in patients with cancer, particularly prostate cancer.<sup>8,16</sup>

Matrix Metalloproteinase (MMP), or matrixin, is a group of free endopeptidase structure that contain zinc, in cooperation with other proteolysis enzymes, such as cysteine proteinases, aspartic proteinase and serine proteinase, which plays a role in extracellular matrix degradation.<sup>8,9</sup> MMP is secreted in the form of proenzyme, then be activated by the proteolytic gap, and this process can be inhibited by Tissue Inhibitor Metalloproteinase (TIMP) in order to avoid degradation. Imbalance between MMP and TIMP is one of the causes of invasion and metastasis that occurs in malignant tumors.<sup>7,8,9,10</sup> Such imbalance is also an important factor that participates in tumor progression.<sup>17</sup> The expression of MMPs



(MMP-2 and MMP-9) is often associated with tumor aggressiveness and overall survival, and it is also often used as a marker of malignancy.<sup>18</sup>

Degradation by MMP in malignancy process is taking place through several stages, including: 1) assisting the formation of a microenvironment through the release of extracellular matrix growth factor; 2) assisting the process of tumor angiogenesis, and enhancing the ability of the migration and invasion of tumor cells; 3) playing a role in angiogenesis at the site of metastasis; 4) playing a role in the damage to basal membrane of blood vessel walls, allowing intravasation and extravasation of tumor cells; and 5) playing a role in shaping new microenvironment at metastasis site.<sup>19</sup>

Positive correlation between blood PSA levels with MMP-2 expression in prostate cancer showed that increased blood PSA level is associated with increased MMP-2 expression in prostate cancer (correlation coefficient (r) 0.431,  $p < 0.05$ ). Increased PSA levels in blood indicates barrier damage caused by invasion through the degradation of collagen type IV, as well as damage caused by MMP-2.<sup>20</sup>

According to Amalinei, Caruntu and Balan (2007), based on the substrate specificity, sequence similarity, and domain organization, MMP is divided into 6 groups: gelatinase (MMP-2, MMP-9); matrilysins (MMP-7, MMP-26); collagenases (MMP-1, MMP-8, MMP-13); stromelysin (MMP-3, MMP-10, MMP-11); membrane-type MMP (MT-MMP -> MMP-14, MMP-15, MMP-17, etc.); and other MMPs (MMP-12, MMP-19, etc.).<sup>20</sup> In addition, the Gleason score is used to assess the tumor grading. It consists of 5 tiered scores ranging from 6 to 10.

Gelatinase-type MMP (MMP-2 and MMP-9) plays an important role because it can degrade collagen types IV, V, VII, X, XI, XIV, gelatin, elastin, proteoglycan core proteins, myelin basic protein, fibronectin, fibrillin-1, a precursor TNF-alpha and IL-1b. MMP-2 is able to break down collagen type I, which is the main component that forms the stroma and break down the molecular structure of collagen type IV which is a most protein constituent of basal membrane and the extra cellular matrix, which is instrumental in the invasion process.<sup>7,8,9,10</sup> Similarly, Murray in 2009 found that the expression of MMP-2 plays a role in the spread of malignant cells through invasion and metastasis.<sup>14</sup> MMP-2 expression (gelatinase A) in some malignant tumors has been widely studied. This relates to the prognostic value. Studies on the MMP-2 have also been started in prostate cancer (adenocarcinoma).

## CONCLUSION

~~There are a correlation between blood PSA level and MMP-2 expression in patients with prostate adenocarcinoma. Blood PSA value in the sample was between 8.6—594.41 ng/ml, showing an increase in serum PSA level.~~ Blood PSA level correlates positively with MMP-2 expression in prostate adenocarcinoma, and increased blood PSA can be used to predict ECM damage in MMP-2-induced prostate adenocarcinoma.

## REFERENCES



- 1 Epstein, JI, Algaba, F, Allbrook, WC, Bastacky, S, et al. Acinar adenocarcinoma, in WHO classification of tumours, pathology and genetics tumours of the urinary system and male genital organs, Ed. Etk JN, IARC Press, Lyon. 2004; hh.161- 92.
- 2 Rosai, J. Male reproductive system. in Rosai and Ackerman's surgical pathology. vol.1, 9th ed, Elsevier, China, 2011; hh. 1361-87.
- 3 Epstein, JI. The lower urinary tract and male genital system, in Robbins pathologic basic of disease, 8th ed, Saunders, Philadelphia, 2010; hh. 993-1003.
- 4 Young, RH. Atlas of tumors pathology, tumors of the prostate gland, seminal vesicles, male uretra, and penis, 3rd series, Armed Forces Institute of Pathology, Washington DC, 2000; hh. 111-200.
- 5 Brehmer B, Biesterfeld S, Jakse G. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue, Prostate Cancer and Prostatic Diseases 6, 2003; 217–222. doi:10.1038/sj.pcan.4500657.  
<http://emedicine.medscape.com/article/457394-overview>
- 6 Nelson RA, Fingleton B, Rothenberg ML, Matrisian LM, Matrix metalloproteinases: Biologic activity and clinical implications, Journal of clinical Oncology, 2000, 218(5):1135-1149.
- 7 Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast cancer res. 2000;2(4):252 - 7.
- 8 Verma RP & Hansch C, Matrix metalloproteinase (MMPs) : chemical-biological function and (Q) SARs; 2007, Bioorg Med Chem 15(6) : 2223-68.
- 9 Tero Leinonen, Risto Pirinen, Jan Bohm, et al. Increased expression of matrix metalloproteinase-2(MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer. In Histol Histopathol; 008; 23: 693-700  
<http://atlasgeneticsoncology.org/Genes/MMP2ID41396ch16q13.html>
- 10 Daniel Kaemmerer, Luisa Peter, Emelie Lupp, et al. Original Article: Comparing of IRS as Immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. Int J Clin Exp Pathol ; 2012;5(3):187- 94
- 11 Stadiana Zivkovic. Original article : Correlation between proatate-specific antigen and histopathological difference of prostate carcinoma. In Arch Oncol; 2004; 12(3); 148-51
- 12 Nigel P. Murray, Gloria M. Calaf, Leonardo Badinez, et al. P504S expressing circulating prostate cells as a marker for prostate cancer. In Oncology Reports; 2010; 24; 687-92
- 13 Dominique trudel, Yves fradet, Franc, et al. Significance of mmp-2 expression in prostate cancer. An immunohistochemical study. In Cancer research ; 2003; 63; 8511–15
- 14 Yixuan Gong, Uma D. Chippada-Venkata, William K. Oh. Reviews: Roles of Matrix metalloproteinase and Their Natural Inhibitors in Prostate Cancer Progression. Cancers; 2014; 6 ; 1298-327
- 15 B Brehmer, S Biesterfeld, G Jakse. Prostate Cancer and Prostatic Disease: Expression of matrix metalloproteinase (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue. 2003; 6; 217-22.
- 16 Romano Oguic, Vladimir Mozetic, Eleonora Cini Tesar, et al. Research article: Matrix metalloproteinase 2 and 9 Immunoexpression in Prostate Carcinoma at the positive Margin of Radical Prostatectomy Specimen. In Hindawi Publishing Corporation Pathology Research International ; 2014; Article ID 262195; 8.  
<http://www.ncbi.nlm.nih.gov/gene/4313>
- 17 Amalinei C, Caruntu ID, Balan RA. Biology of metalloproteinases, Romanian Journal of Morphology and Embryology, 2007; 48 (4) : 323-34.

- 18 Stankovic S, Konjevic G, Gopcevic K, Jovic V, Inic M, Jurisic V. Activity of MMP-2 and MMP-9 in sera of breast cancer patients. *Pathology - Research and Practice*. 2010;206(4):241-7.

## Published Article

# CORRELATION BETWEEN BLOOD SERUM PSA LEVEL AND MMP-2 IN PROSTATE ADENOCARCINOMA

<sup>1</sup>Anny Setijo Rahaju, <sup>1</sup>Aniek Meidi, <sup>1</sup>Gondo Mastutik, <sup>1</sup>Sjahjenny Mustokoweni, <sup>2</sup>Arifa Mustika.

<sup>1</sup>Department of Anatomic Pathology, Faculty of Medicine/Universitas Airlangga, Soetomo General Hospital Surabaya.

<sup>2</sup>Department of Pharmacology, Faculty of Medicine/Universitas Airlangga, Soetomo General Hospital Surabaya.

### ABSTRACT

**Objective:** This study aims to prove the correlation between Prostate Specific Antigen (PSA) blood level and Matrix Metalloproteinase-2 (MMP-2) expression in patients with prostate adenocarcinoma. **Material & method:** Prostate cancer patients' data from January 2009 to May 2012 were collected at the Department of Pathology, Soetomo General Hospital Surabaya. Data collected included patient medical documents, PSA blood examination, and histopathological examination. Histopathology slides and paraffin blocks of needle biopsies, Transurethral Resection of Prostate (TURP) and radical prostatectomy of prostate cancer patients were re-read, then the samples that met the inclusion criteria were stained by immunohistochemistry using antibodies MMP-2. **Results:** Data collection was done to obtain data samples of prostate cancer patients in 2009 to 2012 comprising as many as 22 patients between the ages of 52-91 years. Prostate adenocarcinoma in age of 70-79 was found in 8 patients, with a mean age of 68 years. PSA values obtained from medical documents were between 8.6-594.41 ng/ml. Spearman's test performed in this study showed a positive correlation (one-tailed) (correlation coefficient ( $r$ ) 0.431,  $p < 0.05$ ) between blood PSA level and MMP-2 expression in patients with prostate adenocarcinoma. **Conclusion:** Blood PSA level correlates positively with MMP-2 expression in prostate adenocarcinoma.

**Keywords:** Prostate specific antigen, matrix metalloproteinase-2, prostate adenocarcinoma.

### ABSTRAK

**Tujuan:** Penelitian ini bertujuan untuk membuktikan hubungan antara kadar Prostate Specific Antigen (PSA) darah dengan Ekspresi Matrix Metalloproteinase-2 (MMP-2) pada penderita Adenokarsinoma Prostat. **Bahan & cara:** Data arsip penderita kanker Prostat dikumpulkan di Departemen/SMF/Instalasi Patologi Anatomi RSUD Dr. Soetomo Surabaya, mulai Januari 2009 sampai Mei 2012. Pengumpulan data meliputi dokumen medik penderita, data pemeriksaan PSA darah, dan data pemeriksaan Histopatologi. Slide Histopatologi dan blok parafin hasil biopsi jarum, Transurethral Resection of Prostate (TURP) dan Radikal Prostatectomy penderita kanker prostat dibaca ulang, kemudian sampel memenuhi kriteria inklusi dipulas secara imunohistokimia dengan menggunakan antibodi MMP-2. **Hasil:** Pengumpulan data yang dilakukan memperoleh data sampel penderita kanker prostat pada tahun 2009 sampai 2012 sebanyak 22 orang, yang terjadi antara usia 52-91 tahun. Adenokarsinoma prostat terbanyak terjadi pada usia 70-79 yaitu 8 orang, dengan rerata pada usia 68 tahun. Nilai PSA yang didapatkan pada dokumen medik antara 8.6-594.41 ng/ml. Uji Spearman yang dilakukan pada penelitian ini diperoleh hasil korelasi yang positif (1-tailed) (koefisien korelasi ( $r$ ) 0.431,  $p < 0.05$ ) antara kadar PSA darah dan ekspresi MMP-2 pada penderita adenokarsinoma prostat. **Simpulan:** Terdapat korelasi positif antara kadar PSA darah dengan ekspresi MMP-2 pada adenokarsinoma prostat.

**Kata Kunci:** Prostate specific antigen, matrix metalloproteinase-2, adenokarsinoma prostat.

Correspondence: Anny Setijo Rahaju; c/o: Department of Anatomic Pathology, Faculty of Medicine/Universitas Airlangga, Soetomo General Hospital Surabaya. Jl. Mayjen. Prof. Dr. Moestopo 6-8 Surabaya 60286. Phone: +62 31 5020251, 5030252, 5030253; Fax: +62 31 5026333. Mobile phone: 081803089442. Email: anny\_setijorahaju@yahoo.com.

## INTRODUCTION

Prostate cancer is a malignancy of the sixth most-common of all types of malignancies in the world, and becomes the second leading cause of

death from cancer in men caused by the incidence of metastasis.<sup>1,2</sup> The incidence of prostate cancer in the United States amounted to about 29% of the incidence of all cancers and 10% of the causes of death.<sup>2,3</sup>

Factors contributing to the clinical application of prostate cancer, among others, are the level of Prostate Specific Antigen (PSA) in serum, Gleason grade, tumor stage, and operation edge.<sup>4</sup> These factors have been studied for the development of molecular prognostic markers in prostate cancer. Some literature suggests that malignant tumor cells produce some matrix that can degrade extracellular matrix (ECM), such as Matrix Metalloproteinase (MMP) family that plays a role in the invasion and metastasis of malignancy.<sup>5</sup>

PSA is produced by prostate gland luminal epithelial cells in the form of ductal and acinar, then secreted into the lumen of the gland and excreted along with semen within the seminal vesicles. In prostate cancer (adenocarcinoma) changes in luminal epithelial cells can penetrate and damage basal cells. Changes in luminal epithelial cells and damage in basal cells cause PSA out of the lumen and come into the blood circulation, resulting in increased concentration of PSA in the blood. The increase can be detected in the blood and used for post-therapy screening and evaluation of prostate cancer.<sup>1,2,6</sup>

Adenocarcinoma is a type of prostate cancer that is most commonly found, and in such malignancy there is an imbalance between MMP and Tissue Inhibitor Metalloproteinase (TIMP), which led the invasion into the surrounding tissue and the incidence of metastasis, both lymphogenic and hematogenous.<sup>7-9</sup> MMP-2 is a member of MMP family that has a special composition and function. MMP-2 (gelatinase A), in its function of invasion and metastasis, degrades collagen IV.<sup>10</sup> The invasion and metastasis that occurs in prostate adenocarcinoma can be assessed from the expression of MMP-2 in tumor cells.<sup>11</sup>

## OBJECTIVE

The aim of this study was to prove the correlation between blood serum PSA level and MMP-2 in prostate adenocarcinoma, since studies on the correlation between blood serum PSA levels and MMP-2 expression in prostate adenocarcinoma is rare.

## MATERIAL & METHODS

This study was an observational analytic study with cross-sectional approach conducted by collecting data from the archive on prostate cancer

patients whose diagnosis was established histopathologically as adenocarcinoma of the prostate in the Department of Pathology, Soetomo General Hospital Surabaya, from January 2009 to May 2012. Data collected were in the form of medical documents of the patients, PSA blood examination and histopathological examination data. Histopathology slides and paraffin blocks of needle biopsies, TURP and Radical Prostatectomy from prostate cancer patients were collected, and then re-reading was done to those cases. Samples taken were patients who had data on blood serum PSA examination by ELISA and met the inclusion criteria. Immunohistochemical staining was done by using MMP-2 antibodies to eligible blocks. Results were obtained by conducting analytical testing with Spearman's correlation by comparing the patients' blood PSA with MMP-2 expression in tumor cells. The study was conducted at the Laboratory of Pathology, Faculty of Medicine, Universitas Airlangga, from May to August 2015.

Immunohistochemical staining on paraffin blocks of patients with a diagnosis of prostate adenocarcinoma was performed using antibodies MMP-2. Assessment of MMP-2 expression was done by assessing the expression in the cytoplasm or tumor cell membrane with staining intensity assessment and the percentage of stained tumor cells. Intensity scores are 0 = tumor cells not stained; 1 = light yellow; 2 = brownish yellow and 3 = brown, while the percentage of cell number is multiplied. The determination of the degree of expression was follows: 0 (negative) when the score is 0; 1+ = 1-3; 2+ = 4-6; and 3+ = 7-9.<sup>12</sup> Data on PSA and MMP-2 expression was tested using Spearman rho correlation test, with significant results if  $p < 0.05$ .


## RESULTS

Data collection was done to obtain data on samples of prostate cancer patients from 2009 to 2012 as many as 22 people in ages of 52-91 years. Prostate adenocarcinoma occurred mostly in the age of 70-79, comprising 8 patients, with a mean age 68 years. PSA values obtained from medical documents were between 8.6 - 594.41 ng/ml.


All samples showed positive MMP-2 expression in the cytoplasm and tumor cells membrane, with the percentage as much as 30-70% and > 70%. The intensity varied from light yellow to brown. Then Spearman tests conducted in this study showed a positive correlation (one-tailed) (correla-



tion coefficient ( $r$ ) 0.431,  $p < 0.05$ ) between blood PSA level and MMP-2 expression in patients with prostate adenocarcinoma.





**Figure 1.** Preparation T. 3045/12, percentage > 70% (3+) and intensity 1 MMP-2 intensity I score +



**Figure 2.** Preparation T. 1662/10 percentage > 70% (3+) and intensity 2.

**Table 1.** MMP-2 expression in prostate adenocarcinoma.

MMP-2 expression score	%	I	score
0	0	0	0
1	0	13	13
2	4	5	5
3	18	4	4
Total	22	22	22



**Figure 3.** Preparation T. 3606/11 and 6324/10 percentage > 70% (3+) and intensity 3.

Blood PSA value in the sample was between 8.6–594.41 ng/ml, showing an increase in serum PSA level. Some literature mentions that the normal level is < 4 ng/ml, showing an increase in blood PSA levels compared to normal.<sup>13,14</sup>

## DISCUSSION

The prostate is a retroperitoneal organ that surrounds the bladder neck and urethra, a gland shaped like a pear. Normal prostate gland is composed of two layers of cells: luminal epithelial cells and basal cells. Secretory/luminal cells have a

function to produce seminal fluid in the form of serine protease (prostate specific antigen/PSA).<sup>1,2</sup> Prostate cancer is most commonly in the form of adenocarcinoma, which is an invasive malignant tumor derived from luminal epithelial cells. In adenocarcinoma luminal epithelial cells change and able to penetrate basal cells, resulting in basal cell damage. Changes in luminal epithelial cells and damage in basal cells cause the produced PSA out of the lumen and enters blood circulation, resulting in increased PSA concentration in blood. The increase can be detected in blood and is used for screening and evaluation of prostate cancer post-treatment as well as indications for biopsy in patients. PSA is also a marker that is often used to diagnose prostate cancer.<sup>1,2,6</sup>

Murray in 2010 also stated that blood PSA value was positively related to the number of malignant epithelial cells stained with immunohistochemical staining with PSA antibody. Increasing number of malignant epithelial cells results in increased blood PSA level, indicating that more malignant cells that damage the barrier will lead to higher levels of PSA detected in the circulation.<sup>14</sup>

The process of cell integrity disruption causes the release of PSA in circulation. This integration disorder also occurs in hyperplasia, inflammation and tumors. PSA value in benign prostate tissue:  $0.5 \pm 0.4$  ng/ml, in BPH:  $0:31 \pm 0:25$  ng/ml, so that up to now there is no definite value in cancer.<sup>6</sup>

Zivkovic in 2004 obtain levels of 4.0-10.0 ng/ml in benign hyperplasia, prostatitis and prostate cancer. Murray conducted a study in 2010 by measuring the weight of prostate tissue, giving results that each gram of prostate cancer tissue can increase PSA of approximately 2.3 ng/ml. Hyperplastic prostate tissue is 10 times lower than cancerous tissue. In addition, they also found that the highest PSA level was in the lumen of the prostate gland, and between gland lumen and capillary blood vessel, basal cells in the gland, prostate stromal and capillary endothelial cells they found barrier that prevents PSA to circulate in the circulation. Therefore, PSA can increase drastically in the state of prostatitis, but can return to normal after the infection resolved.<sup>14</sup>

All samples of this study showed positive expression of MMP-2, according to a study by Trudel (2003), who found that 70% of malignant epithelial cells had positive expression of MMP-2

due to the degradation of ECM by MMP-2.<sup>15</sup> There was a positive correlation between blood PSA levels with MMP-2 expression in prostate cancer, showing that increased blood PSA level is associated with increased MMP-2 expression in prostate cancer (correlation coefficient (r) 0.431,  $p < 0.05$ ).

Malignant cells produce matrix that actively degrades with different specific substrates that act together in the degradation of Extracellular Matrix (ECM), that is the Matrix Metalloproteinase (MMP) family, which is associated with the invasion and metastasis of tumor cells. This tumor metastases is the main cause of death in patients with cancer, particularly prostate cancer.<sup>8,16</sup>

Matrix Metalloproteinase (MMP), or matrix in, is a group of free endopeptidase structure that contain zinc, in cooperation with other proteolysis enzymes, such as cysteine proteinases, aspartic proteinase and serine proteinase, which plays a role in extracellular matrix degradation.<sup>8,9</sup> MMP is secreted in the form of proenzyme, then be activated by the proteolytic gap, and this process can be inhibited by Tissue Inhibitor Metalloproteinase (TIMP) in order to avoid degradation. Imbalance between MMP and TIMP is one of the causes of invasion and metastasis that occurs in malignant tumors.<sup>7-10</sup> Such imbalance is also an important factor that participates in tumor progression.<sup>17</sup> The expression of MMPs (MMP-2 and MMP-9) is often associated with tumor aggressiveness and overall survival, and it is also often used as a marker of malignancy.<sup>18</sup>

Degradation by MMP in malignancy process is taking place through several stages, including: 1) assisting the formation of a micro-environment through the release of extracellular matrix growth factor; 2) assisting the process of tumor angiogenesis, and enhancing the ability of the migration and invasion of tumor cells; 3) playing a role in angiogenesis at the site of metastasis; 4) playing a role in the damage to basal membrane of blood vessel walls, allowing intravasation and extravasation of tumor cells; and 5) playing a role in shaping new microenvironment at metastasis site.<sup>19</sup>

Positive correlation between blood PSA levels with MMP-2 expression in prostate cancer showed that increased blood PSA level is associated with increased MMP-2 expression in prostate cancer (correlation coefficient (r) 0.431,  $p < 0.05$ ). Increased PSA levels in blood indicates barrier damage caused by invasion through the degradation of collagen type IV, as well as damage caused by MMP-2.<sup>20</sup>



According to Amalinei, Caruntu and Balan (2007), based on the substrate specificity, sequence similarity, and domain organization, MMP is divided into 6 groups: gelatinase (MMP-2, MMP-9); matrilysins (MMP-7, MMP-26); collagenases (MMP-1, MMP-8, MMP-13); stromelysin (MMP-3, MMP-10, MMP-11); membrane-type MMP (MT-MMP -> MMP-14, MMP-15, MMP-17, etc.); and other MMPs (MMP-12, MMP-19, etc.).<sup>20</sup>

Gelatinase-type MMP (MMP-2 and MMP-9) plays an important role because it can degrade collagen types IV, V, VII, X, XI, XIV, gelatin, elastin, proteoglycan core proteins, myelin basic protein, fibronectin, fibrillin-1, a precursor TNF-alpha and IL-1b. MMP-2 is able to break down collagen type I, which is the main component that forms the stroma and break down the molecular structure of collagen type IV which is a most protein constituent of basal membrane and the extra cellular matrix, which is instrumental in the invasion process.<sup>7-10</sup> Similarly, Murray in 2009 found that the expression of MMP-2 plays a role in the spread of malignant cells through invasion and metastasis.<sup>14</sup> MMP-2 expression (gelatinase A) in some malignant tumors has been widely studied. This relates to the prognostic value. Studies on the MMP-2 have also been started in prostate cancer (adenocarcinoma).

## CONCLUSION

Blood PSA level correlates positively with MMP-2 expression in prostate adenocarcinoma and increased blood PSA can be used to predict ECM damage in MMP-2-induced prostate adenocarcinoma.

## REFERENCES

- 1 Epstein, JI, Algaba, F, Allbrook, WC, Bastacky, S. Acinar adenocarcinoma, in WHO classification of tumours, pathology and genetics tumours of the urinary system and male genital organs, Ed. Ebk JN, IARC Press, Lyon; 2004. p. 161-92.
- 2 Rosai, J. Male reproductive system. In Rosai and Ackerman's surgical pathology. 9<sup>th</sup> Ed. Elsevier, China. 2011; 1: 1361-87.
- 3 Epstein, JI. The lower urinary tract and male genital system, in Robbins pathologic basic of disease, 8<sup>th</sup> Ed. Saunders: Philadelphia; 2010. p. 993-1003.
- 4 Young, RH. Atlas of tumors pathology, tumors of the prostate gland, seminal vesicles, male uretra, and penis, 3<sup>rd</sup> Series. Armed Forces Institute of Pathology: Washington DC; 2000. p. 111-200.
- 5 Brehmer B, Biesterfeld S, Jakse G. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue, Prostate Cancer and Prostatic Diseases 6; 2003. p. 217-22. doi:10.1038/sj.pcan.4500657.
- 6 <http://emedicine.medscape.com/article/457394-overview>
- 7 Nelson RA, Fingleton B, Rothenberg ML, Matrisian LM, Matrix metalloproteinases: Biologic activity and clinical implications, Journal of Clinical Oncology. 2000; 218(5): 1135-49.
- 8 Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2000; 2(4): 252-7.
- 9 Verma RP, Hansch C. Matrix metalloproteinase (MMPs): chemical-biological function and (Q) SARs. Bioorg Med Chem. 2007; 15(6): 2223-68.
- 10 Tero Leinonen, Risto Pirinen, Jan Bohm. Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer. In Histol Histopathol. 2008; 23: 693-700.
- 11 <http://atlasgeneticsoncology.org/Genes/MMP2ID4136ch16q13.html>
- 12 Daniel Kaemmerer, Luisa Peter, Emelie Lupp. Original Article: Comparing of IRS as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. Int J Clin Exp Pathol. 2012; 5(3): 187-94
- 13 Stadiana Zivkovic. Original article: Correlation between prostate-specific antigen and histopathological difference of prostate carcinoma. In Arch Oncol. 2004; 12(3): 148-51.
- 14 Nigel P. Murray, Gloria M. Calaf, Leonardo Badinez. P504S expressing circulating prostate cells as a marker for prostate cancer. In Oncology Reports. 2010; 24; 687-92.
- 15 Dominique trudel, Yves fradet, Franc. Significance of MMP-2 expression in prostate cancer. An immunohistochemical study. In Cancer research. 2003; 63; 8511-15.
- 16 Yixuan Gong, Uma D. Chippada-Venkata, William K. Oh. Reviews: Roles of matrix metalloproteinase and their natural inhibitors in prostate cancer progression. Cancers. 2014; 6: 1298-327.
- 17 B Brehmer, S Biesterfeld, G Jakse. Prostate cancer and prostatic disease: Expression of matrix metalloproteinase (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue. 2003; 6; 217-22.
- 18 Romano Oguic, Vladimir Mozetic, Eleonora Cini Tesar. Research article: Matrix metalloproteinase 2 and 9 immunoexpression in prostate carcinoma at the positive margin of radical prostatectomy specimen. In Hindawi Publishing Corporation Pathology Research International; 2014. Article ID 262195; 8.
- 19 <http://www.ncbi.nlm.nih.gov/gene/4313>.

20 Amalinei C, Caruntu ID, Balan RA. Biology of metalloproteinases. Romanian Journal of Morpho-

logy and Embryology. 2007; 48(4): 323-34.